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1. PREAMBLE
Guidelines and Focused Updates written under the auspices of
the European Society of Cardiology’s (ESC) Committee for
Practice Guidelines (CPG) summarize and evaluate available evi-
dence with the aim of assisting health professionals in selecting
the best management strategies for an individual patient with a
given condition. The CPG Guidelines’ and Focused Updates’ rec-
ommendations should facilitate decision making of health pro-
fessionals in their daily practice. However, the final decisions
concerning an individual patient must be made by the respon-
sible health professional(s) in consultation with the patient and
caregiver as appropriate.
A great number of guidelines and focused updates have been
issued in recent years by the ESC and by the European Association
for Cardio-Thoracic Surgery (EACTS) as well as by other societies
and organizations. Because of the impact on clinical practice, qual-
ity criteria for the development of guidelines have been estab-
lished in order to make all decisions transparent to the user. The
recommendations for formulating and issuing ESC Guidelines can
be found on the ESC website (http://www.escardio.org/Guidelines-
&-Education/Clinical-Practice-Guidelines/Guidelines-development/
Writing-ESC-Guidelines). ESC Guidelines represent the official pos-
ition of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC and
EACTS to represent professionals involved with the medical care
of patients with this pathology. Selected experts in the field
undertook a comprehensive review of the published evidence for
management of a given condition according to ESC Committee
for Practice Guidelines (CPG) policy and approved by the EACTS.
A critical evaluation of diagnostic and therapeutic procedures
was performed, including assessment of the risk–benefit ratio.
The level of evidence and the strength of the recommendation of
particular management options were weighed and graded ac-
cording to predefined scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided dec-
laration of interest forms for all relationships that might be per-
ceived as real or potential sources of conflicts of interest. These
forms were compiled into one file and can be found on the ESC
website (http://www.escardio.org/guidelines). Any changes in
declarations of interest that arise during the writing period were
notified to the ESC and updated. The Task Force received its en-
tire financial support from the ESC without any involvement
from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of
new Guidelines and of its Focused Updates. The Committee is
also responsible for the endorsement process of these docu-
ments. These CPG documents undergo extensive review by the
CPG and external experts, and in this case by EACTS-appointed
experts. After appropriate revisions the CPG documents are
approved by all the experts involved in the Task Force. The final-
ized document is approved by the CPG for publication in the
European Heart Journal and in the European Journal of Cardio-
Thoracic Surgery. These CPG documents were developed after
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careful consideration of the scientific and medical knowledge
and the evidence available at the time of their dating.
The task of developing this CPG Focused Update in collabor-
ation with EACTS also includes the creation of educational tools
and implementation programmes for the recommendations
including condensed pocket guideline versions, summary slides,
and an electronic version for digital applications (smartphones,
etc.) as well as other educational tools depending on the topic.
These versions are abridged and thus, if needed, one should al-
ways refer to the full text version, which is freely available via the
ESC website and hosted on the EHJ website. The National
Societies of the ESC are encouraged to endorse, translate and im-
plement all ESC Guidelines. Implementation programmes are
needed because it has been shown that the outcome of disease
may be favourably influenced by the thorough application of
clinical recommendations.
Surveys and registries are needed to verify that real-life daily
practice is in keeping with what is recommended in the guide-
lines, thus completing the loop between clinical research, writing
of guidelines and official focused updates, disseminating them
and implementing them into clinical practice.
Health professionals are encouraged to take the ESC CPG
Guidelines and Focused Updates developed in collaboration with
EACTS fully into account when exercising their clinical judgment,
as well as in the determination and the implementation of pre-
ventive, diagnostic or therapeutic medical strategies. However,
the CPG documents do not override in any way whatsoever the
individual responsibility of health professionals to make appro-
priate and accurate decisions in consideration of each patient’s
health condition and in consultation with that patient or the pa-
tient’s caregiver where appropriate and/or necessary. It is also
the health professional’s responsibility to verify the rules and
regulations applicable to drugs and devices at the time of
prescription.
2. INTRODUCTION
The estimated number of patients requiring dual antiplatelet therapy
(DAPT), consisting of the combination of aspirin and an oral inhibi-
tor of the platelet P2Y12 receptor for adenosine 5’-diphosphate
(ADP), is considerable and has increased over time in Europe. Based
on population estimates from 2015, in the region of 1 400 000 and
2 200 000 patients per year may have an indication for DAPT after
coronary intervention or myocardial infarction (MI), respectively [1].
This year, 2017, is the 21st anniversary of the publication of
the first randomized clinical trial to establish the superiority of
Table 2: Levels of evidence
Table 1: Classes of recommendations
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DAPT over anticoagulant therapy among patients undergoing
percutaneous coronary intervention (PCI) (Figure 1) [2]. Based on
over 35 randomized clinical trials, including more than 225 000
patients, DAPT is among the most intensively investigated treat-
ment options in the field of cardiovascular medicine. Along with
progressive refinement of P2Y12 inhibition strategies—embracing
firstly safer (from ticlopidine to clopidogrel) and then more po-
tent and predictable (from clopidogrel to ticagrelor or prasugrel)
drugs—research has concomitantly focused on optimal treatment
duration. The need to investigate longer DAPT regimens firstly
arose from concerns over late and very late stent thrombosis
occurring after first-generation drug-eluting stent (DES) implant-
ation [3]. Yet, the advent of safer newer-generation DESs and the
results of the most recent randomized controlled trials (RCTs)
have established a major paradigm shift in the way DAPT should
be conceived and used in clinical practice. DAPT remains a highly
effective preventive treatment for stent thrombosis across the
board; however, the risks of late and (even more) very late stent
thrombosis have declined considerably since the advent of
newer-generation DESs. Hence, the risk of bleeding associated
with DAPT prolongation beyond 1 year does not seem to be jus-
tified by the small absolute benefit observed in terms of very late
stent thrombosis prevention. On the other hand, there is emerg-
ing evidence that DAPT reduces the long-term risk of non-stent-
related MI as well as stroke. Hence, after 21 years of research,
DAPT has moved from a local (i.e. stent-related) to a systemic
treatment strategy (i.e. capable of preventing thrombotic arterial
vessel occlusion), conveying global patient protection (Figure 1).
There is, however, confusion in the community around the opti-
mal type and duration of DAPT in patients with established coronary
artery disease (CAD), undergoing coronary revascularization or not
[4]. This derives from apparently conflicting results arising from the
available studies and limited evidence on various patient subsets
(e.g. elderly patients, with comorbidities or at greater bleeding risk)
in whom the trade-off between the benefits and risks of DAPT may
differ from those observed in more selected patient cohorts
included in trials. Therefore, the scope of this focused update is to
address recommendations on DAPT in patients with CAD.
2.1 Short- and long-term outcomes after percuta-
neous coronary intervention
See Web Addenda.
2.2 Risk of stent thrombosis in relation to stent
type
See Web Addenda.
2.3 Short- and long-term outcomes after coronary
artery bypass surgery
See Web Addenda.
2.4 Short- and long-term outcomes after medically
managed acute coronary syndrome
See Web Addenda.
Figure 1: History of dual antiplatelet therapy (DAPT) in patients with coronary artery disease. The size of the circles denotes sample size. The colours of perimeters
identify the type of included patient populations within each study. The colours within each circle identify the antiplatelet agent(s) investigated. Head-to-head studies
comparing similar durations of two different antiplatelet strategies are shown with a vertical line, whereas those investigating different treatment durations are shown
with a horizontal line. Studies investigating different treatment strategies or regimens and not treatment durations or type (e.g. pre-treatment in ACCOAST, tailored
therapy in GRAVITAS, double dose of clopidogrel in CURRENT OASIS 7, etc.) are represented with a single colour indicating the P2Y12 inhibitor, which was tested on
top of aspirin.
pts = patients.
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3. EFFICACY AND SAFETY OF DUAL
ANTIPLATELET THERAPY AND RISK
STRATIFICATION TOOLS
Current evidence suggests that DAPT mitigates the risk of stent
thrombosis across the whole spectrum, from acute to very late
events. However, treatment with DAPT beyond 1 year after MI, or
after PCI, exerts the majority of its benefit by reducing the rate of
spontaneous MI, which is associated with mortality rates of 15%
[5]. Nonetheless, because continued antiplatelet therapy is also
associated with increased bleeding risk, it is necessary to weigh
this risk against the potential benefit. Current evidence suggests
that the risk of bleeding in patients on DAPT is proportionally
related to its duration both within and beyond 1 year of treatment
duration. Since the benefits of prolonged DAPT, especially for
mortality endpoints, appear highly dependent on prior cardiovas-
cular history [such as prior acute coronary syndrome (ACS)/MI vs.
stable CAD], and prediction models to estimate on-DAPT bleeding
risk have been developed, an individualized approach based on is-
chaemic vs. bleeding risk assessment is warranted.
3.1 Dual antiplatelet therapy for the prevention of
stent thrombosis
See Web Addenda.
3.2 Dual antiplatelet therapy for the prevention of
spontaneous myocardial infarction
See Web Addenda.
3.3 Dual antiplatelet therapy and mortality rate
See Web Addenda.
3.4 Safety of dual antiplatelet therapy
See Web Addenda.
3.5 Risk stratification tools for ischaemia and
bleeding risks
Given the trade-off between ischaemic vs. bleeding risks for any
given DAPT duration, the use of scores might prove useful to tai-
lor DAPT duration in order to maximize ischaemic protection
and minimize bleeding risks in the individual patient [6]. Most
of the frequently used risk scores for assessing ischaemic events
[7–9] and major bleeds [10–12] were originally developed and
validated for the prediction of events occurring mainly during
hospital stay or early on thereafter [13, 14]. As a result, the appli-
cation of these risk scores to decide upon DAPT duration remains
problematic, as only limited data exist exploring their value to
guide DAPT duration [13]. On the other hand, the use of risk
scores that were specifically designed to guide and inform deci-
sion making on DAPT duration should be prioritized over other
available risk scores (Table 3).
The DAPT score was developed from 11 648 patients enrolled
in the DAPT trial and was initially validated in 8136 patients en-
rolled in the Patient-Related Outcomes With Endeavor vs.
Cypher Stenting (PROTECT) trial [15]. This prediction rule identi-
fied nine factors [age, congestive heart failure/low left ventricular
ejection fraction (LVEF), vein graft stenting, MI at presentation,
prior MI or PCI, diabetes, stent diameter <3 mm, smoking, and
paclitaxel-eluting stent] resulting in a score ranging from -2 to +
10. Within the DAPT trial, a high-risk score (i.e. a score >_2) se-
lected patients who showed a reduction in MI/stent thrombosis
and cardiovascular or cerebrovascular events risk [number
needed to treat (NNT) for benefit for ischaemic event reduction
= 34] after a prolonged, 30-month DAPT, with only a modest in-
crease in bleeding risk (NNT for harm = 272). In turn, a low-risk
score (<2) selected patients recruited in the DAPT trial who did
not derive any reduction of ischaemic events from prolonging
DAPT, with a significant increase in moderate/major bleeding
(NNT for harm = 64). As DAPT duration was not randomized in
the PROTECT trial, the value of the DAPT score in guiding the
duration of therapy has so far only been shown for patients re-
cruited to the DAPT trial. Additional validation of the DAPT score
to guide DAPT duration is needed, especially in the context of
less well-selected patients as compared to those recruited in the
DAPT trial and undergoing treatment with new-generation DES
only.
Two independent predictive scores for bleeding [age, body
mass index, smoking, anaemia, creatinine clearance (CrCl), and
triple therapy at discharge] and MI or stent thrombosis [diabetes
mellitus, ACS, smoking, CrCl, prior PCI, and prior coronary artery
bypass graft surgery (CABG)] have also been developed from the
Patterns of Nonadherence to Antiplatelet Regimens in Stented
Patients (PARIS) registry [16]. PARIS was a prospective, multi-
centre, observational study of patients undergoing PCI with stent
implantation in the USA and Europe, which was designed to
examine the different modes of DAPT cessation and to investi-
gate the influence of these modes on subsequent clinical adverse
events [17]. This registry study included patients with an indica-
tion for oral anticoagulation. The value of the PARIS bleeding
and/or ischaemic risk scores to tailor DAPT duration remains un-
clear, since therapy duration was not randomized in the PARIS
study and no study to date has applied the results of these scores
for DAPT type or duration guidance. A high ischaemic risk status
was observed in roughly 40% of high bleeding risk patients [16]
and as many as 65.3% presented low ischaemic and bleeding
risks [16]. Therefore, it remains unclear how DAPT duration
should be guided by the simultaneous assessment of ischaemic
and bleeding risk features according to PARIS.
The PRECISE-DAPT (PREdicting bleeding Complications In pa-
tients undergoing Stent implantation and subsEquent Dual Anti
Platelet Therapy) collaborative study included a total of 14 963
patients with CAD who underwent elective, urgent, or emergent
PCI and generated a five-item (age, CrCl, haemoglobin, white
blood cell count, and prior spontaneous bleeding) prediction al-
gorithm for out-of-hospital bleeding in patients treated with
DAPT [18].
The predictive performance of this novel score was assessed in
the derivation cohort and validated in 8595 and 6172 patients
treated with PCI from the PLATelet inhibition and patient Outcomes
(PLATO) trial and the Bern PCI registry [19, 20], respectively.
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The PRECISE-DAPT score showed improved integrated discrimin-
ation and reclassification performance as compared to the PARIS
bleeding score in both validation cohorts [18]. The usefulness of this
score was also assessed within patients randomized to different
DAPT durations (n = 10 081) to identify the effect on bleeding and
ischaemia of a long (12–24 months) or short (3–6 months) treatment
duration in relation to baseline bleeding risk. It was observed that
among patients deemed at high bleeding risk based on PRECISE-
DAPT (PRECISE-DAPT score >_25), prolonged DAPT was associated
with no ischaemic benefit but a remarkable bleeding burden leading
to an NNT for harm of 38 [18]. On the other hand, longer treatment
in patients without high bleeding risk (PRECISE-DAPT score <25)
was associated with no increase in bleeding and a significant reduc-
tion in the composite ischaemic endpoint of MI, definite stent
thrombosis, stroke, and target vessel revascularization, with an NNT
for benefit of 65 [18]. Selecting a shorter than 12-month treatment
duration in patients deemed at high bleeding risk upfront may
therefore prevent their exposure to an excessive bleeding hazard. In
turn, patients at non-high bleeding risk might receive a standard (i.e.
12 months) or prolonged (i.e. >12 months) course of treatment if
tolerated.
However, none of these risk prediction models have been pro-
spectively tested in the setting of RCTs. Therefore, their value in
improving patient outcomes remains unclear.
3.6 Type of P2Y12 inhibitor and timing of initiation
Clopidogrel: Clopidogrel is associated with a better safety profile
than ticlopidine, mainly in terms of allergy, skin or gastrointes-
tinal disorders, and neutropenia, while it has a similar degree and
consistency of P2Y12 inhibition and bleeding risk [21, 22]. The
wide variability in the pharmacodynamic response to ticlopidine
Table 3: Risk scores validated for dual antiplatelet therapy duration decision-making
CHF: congestive heart failure; CrCl: creatinine clearance; DAPT: dual antiplatelet therapy; Hb: haemoglobin; LVEF: left ventricular ejection fraction; MI: myocar-
dial infarction; PCI: percutaneous coronary intervention; PRECISE-DAPT: PREdicting bleeding Complications In patients undergoing Stent implantation and
subsEquent Dual Anti Platelet Therapy; WBC: white blood cell count.
aFor the PRECISE-DAPT score use the score nomogram: mark patient’s value for each of the five clinical variables of the score and draw a vertical line to the
‘Point’ axis to determine the number of points obtained for each clinical variable. Than summate the points obtained for each clinical variable to the total
score. A practical case example for score calculation is provided in Web Figure 1 of the Web Addenda.
For the DAPT score summate positive points for each value and subtract values for age to the total score.
Use of risk scores as guidance for the duration of dual
antiplatelet therapy
Recommendations Classa Levelb
The use of risk scores designed to evaluate
the benefits and risks of different DAPT dur-
ationsc may be considered [15, 18].
IIb A
DAPT: dual antiplatelet therapy.
aClass of recommendation.
bLevel of evidence.
cThe DAPT and PRECISE-DAPT scores are those currently fulfilling these
requirements.
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and clopidogrel is linked to several factors, including genotype
polymorphisms [22]. Clinical evidence with respect to the optimal
duration of clopidogrel therapy after PCI is discussed elsewhere
(Chapter 4).
Prasugrel: Prasugrel achieves a faster, greater, and more con-
sistent degree of P2Y12 inhibition as compared to clopidogrel.
Prasugrel requires two metabolic steps for formation of its active
metabolite, which is chemically similar to the active metabolite
of clopidogrel. The Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis in Myocardial Infarction (TRITON-TIMI 38)
included P2Y12 inhibitor-naı̈ve ACS patients in whom coronary
anatomy was deemed suitable for PCI, or patients with ST-
segment elevation myocardial infarction (STEMI) referred for pri-
mary PCI [23]. Duration of DAPT was up to 15 months in both
study arms. The composite primary endpoint (cardiovascular
death, non-fatal MI, or stroke) occurred in 9.3% of prasugrel-
treated patients vs. 11.2% of clopidogrel-treated patients [hazard
ratio (HR) 0.82, 95% confidence interval (CI) 0.73–0.93; P =
0.002], mostly driven by a significant risk reduction for MI [from
9.2% to 7.1%; relative risk reduction (RRR) 23.9%, 95% CI 12.7–
33.7; P < 0.001) [23]. There was no difference in the rates of either
non-fatal stroke or cardiovascular death.
Prasugrel was associated with a significant increase in the rate of
non-CABG-related TIMI major bleeding (2.4% vs. 1.8%; HR 1.32,
95% CI 1.03–1.68; P = 0.03). Life-threatening bleeding was signifi-
cantly increased under prasugrel compared with clopidogrel (1.4%
vs. 0.9%; HR 1.52, 95% CI 1.08–2.13; P = 0.01), as was fatal bleeding
(0.4% vs. 0.1%, HR 4.19, 95% CI 1.58–11.11; P = 0.002). CABG-
related bleeding was also higher in prasugrel-treated patients
(13.4% vs. 3.2%; HR 4.72, 95% CI 1.90–11.82; P < 0.001). There was
evidence of net harm with prasugrel in patients with a history of
cerebrovascular events. In addition, there was no apparent net
clinical benefit in patients >_75 years of age and in patients with low
body weight (<60 kg) [23]. Prasugrel was not tested in medically
managed ACS patients in the setting of the TRITON-TIMI 38 study.
In the Targeted Platelet Inhibition to Clarify the Optimal Strategy
to Medically Manage Acute Coronary Syndromes (TRILOGY ACS)
study, which exclusively included medically managed ACS patients,
the primary endpoint of death from cardiovascular causes, MI, or
stroke among patients under the age of 75 years occurred in 13.9%
of the prasugrel group and 16.0% of the clopidogrel group (HR
0.91, 95% CI 0.79–1.05; P = 0.21), at a median follow-up of
17 months [24]. Similar results were observed in the overall popu-
lation (i.e. also including elderly patients). Hence, prasugrel is not
indicated in medically managed ACS patients.
The TRITON-TIMI 38 study mandated the use of prasugrel or
clopidogrel after coronary angiography if an indication to pro-
ceed to PCI was established. Pre-treatment was allowed only in
STEMI patients undergoing primary intervention (n = 2438).
For the comparison of prasugrel at the time of PCI, in the A
Comparison of Prasugrel at the Time of Percutaneous Coronary
Intervention Or as Pretreatment At the Time of Diagnosis in Patients
with Non-ST-Elevation Myocardial Infarction (ACCOAST), 4033 pa-
tients with non-STEMI (NSTEMI) who were scheduled to undergo
coronary angiography within 2–48 h after randomization were as-
signed to receive prasugrel (a 30 mg loading dose) before angiog-
raphy (pre-treatment group) or placebo (control group) [25]. When
PCI was indicated, an additional 30 mg of prasugrel was given in the
pre-treatment group at the time of PCI and 60 mg of prasugrel was
given in the control group. The rate of the primary efficacy endpoint,
a composite of death from cardiovascular causes, MI, stroke, urgent
revascularization, or glycoprotein IIb/IIIa inhibitor rescue therapy
(glycoprotein IIb/IIIa bailout) through day 7, did not differ signifi-
cantly between the two groups (HR with pre-treatment 1.02, 95% CI
0.84–1.25; P = 0.81) [25]. The rate of the key safety endpoint of all
TIMI major bleeding episodes, whether related to CABG or not,
through day 7 was increased with pre-treatment (HR 1.90, 95% CI
1.19–3.02; P = 0.006). The rates of TIMI major bleeding and life-
threatening bleeding not related to CABG were increased by a factor
of 3 and 6, respectively. Pre-treatment did not reduce the rate of the
primary outcome among patients undergoing PCI (69% of the pa-
tients) but increased the rate of TIMI major bleeding at 7 days [25].
Hence, prasugrel is not indicated in patients with ACS in whom
coronary anatomy is not known and an indication for PCI is not
clearly established, with the exception of STEMI patients scheduled
to undergo immediate coronary catheterization and PCI, if clinically
indicated.
In the DAPT trial, 3461 patients (34.7% of the total trial population)
who were treated with prasugrel within the first 12 months after
intervention were randomly allocated to stop or continue the treat-
ment for an additional 18 months [26]. The type of P2Y12 inhibitor or
stent type were not randomized for. However, the largest cohort of
prasugrel-treated patients (n = 2191) was provided by the TAXUS
Liberté Post Approval Study (TL-PAS), which was a prospective, multi-
centre, open-label study developed to review the clinical perform-
ance of the Taxus Liberté paclitaxel-eluting stent in routine clinical
practice in the USA [27]. Enrolled TL-PAS patients received open-
label prasugrel plus aspirin for 12 months after stent placement; en-
rolment was not restricted to patients presenting with ACS (i.e. those
with an approved indication for prasugrel). Rates of death and stroke
were similar between groups, but MI was significantly reduced with
prolonged prasugrel treatment (1.9% vs. 7.1%; HR 0.255; P < 0.001).
The DAPT co-primary endpoint, stent thrombosis, was also lower
with longer therapy (0.2% vs. 2.9%; HR 0.063; P < 0.001). The safety
endpoint of GUSTO (Global Use of Strategies to Open Occluded
Coronary Arteries) moderate or severe bleeding was numerically
increased in the patients continuing prasugrel to 30 months, although
the difference was not statistically significant (2.4% vs. 1.7%; HR
1.438; P = 0.234) [27]. No subgroup data have been provided among
patients treated with prasugrel with respect to indication for PCI (i.e.
ACS vs. stable CAD) or type of implanted stent (i.e. paclitaxel-eluting
stent vs. other stent types).
Ticagrelor: Ticagrelor belongs to a novel chemical class, cyclo-
pentyl triazolopyrimidine, and is a direct oral, reversibly binding
P2Y12 inhibitor with a plasma half-life of 12 h. In the PLATO trial,
ticagrelor proved to be superior to clopidogrel in ACS patients,
who were allowed to be pre-treated with clopidogrel at hospital
admission, irrespective of the final revascularization strategy (i.e.
planned or not planned invasive management) [20]. Patients with
either moderate- to high-risk non-ST elevation ACS (NSTE-ACS)
(planned for either conservative or invasive management) or
STEMI planned for primary PCI were randomized to either clopi-
dogrel 75 mg daily, with a loading dose of 300 mg, or ticagrelor
180 mg loading dose followed by 90 mg twice daily [20]. Patients
undergoing PCI were allowed to receive an additional blinded
300 mg loading dose of clopidogrel (total loading dose 600 mg) or
its placebo, and were also recommended to receive an additional
90 mg of ticagrelor (or its placebo) if >24 h after the initial loading
dose. Treatment was continued for up to 12 months, with a min-
imum intended treatment duration of 6 months and a median
duration of study drug exposure of 9 months [20].
In the overall cohort, the primary composite efficacy endpoint
(death from vascular causes, MI, or stroke) was observed in 9.8% of
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the patients in the ticagrelor group and in 11.7% of the patients in
the clopidogrel group (HR 0.84, 95% CI 0.77–0.92; P < 0.001) [20].
According to the pre-defined statistical analysis plan, death from
vascular causes was significantly reduced from 5.1% to 4.0% (HR
0.79, 95% CI 0.69–0.91; P = 0.001), and from MI from 6.9% to 5.8%
(HR 0.84, 95% CI 0.75–0.95; P = 0.005). There was no significant dif-
ference in the rates of stroke (1.3% vs. 1.5%; P = 0.22). The rate of
definite stent thrombosis was reduced from 1.9% to 1.3% (P < 0.01)
and total mortality from 5.9% to 4.5% (P < 0.001). Overall, there
was no significant difference in PLATO-defined major bleeding
rates between the clopidogrel and ticagrelor groups (11.2% vs.
11.6%, respectively; P = 0.43). Major bleeding unrelated to CABG
was increased from 3.8% in the clopidogrel group to 4.5% in the
ticagrelor group (HR 1.19, 95% CI 1.02–1.38; P = 0.03). Major bleed-
ing related to CABG was similar with ticagrelor and clopidogrel
(7.4% vs. 7.9%, respectively; P = 0.32). There was no difference in
the overall rates of fatal haemorrhage between the groups (0.3% in
both groups). The superiority of ticagrelor over clopidogrel with re-
spect to the primary study endpoint as well as cardiovascular death
or overall mortality was consistent across management strategies,
i.e. patients undergoing PCI, those medically managed, and patients
who underwent CABG [20].
No dedicated study exists assessing the value of early (i.e. before
coronary angiography) vs. delayed (i.e. after coronary angiography)
ticagrelor administration in patients with NSTE-ACS. The
Administration of Ticagrelor in the Cath Lab or in the Ambulance
for New ST Elevation Myocardial Infarction to Open the Coronary
Artery (ATLANTIC) study involved 1862 patients with STEMI <6-h
duration and compared pre-hospital (in the ambulance) vs. in-
hospital (in the catheterization laboratory) treatment with ticagrelor
[28]. The co-primary endpoints were the proportion of patients who
did not have >_70% resolution of ST-segment elevation before PCI
and the proportion of patients who did not have TIMI flow grade 3
in the infarct-related artery at initial angiography. Secondary end-
points included the rates of major adverse cardiovascular events
(MACE) and definite stent thrombosis at 30 days. The median time
difference between the two treatment strategies was 31 min. The
two co-primary endpoints did not differ significantly between the
pre-hospital and in-hospital groups. The rates of definite stent
thrombosis were lower in the pre-hospital group than in the in-
hospital group (0% vs. 0.8%, P = 0.008 in the first 24 h; 0.2% vs.
1.2%, P = 0.02 at 30 days). Rates of major bleeding events were low
and virtually identical in the two groups, regardless of the bleeding
definition used [28].
Recommendations on P2Y12 inhibitor selection and timing
Recommendations Classa Levelb
In patients with ACS, ticagrelor (180 mg loading dose, 90 mg twice daily) on top of aspirinc is recommended, regardless of ini-
tial treatment strategy, including patients pre-treated with clopidogrel (which should be discontinued when ticagrelor is com-
menced) unless there are contraindications [20].
I B
In patients with ACS undergoing PCI, prasugrel (60 mg loading dose, 10 mg daily dose) on top of aspirin is recommended for
P2Y12 inhibitor-naı̈ve patients with NSTE-ACS or initially conservatively managed STEMI if indication for PCI is established, or
in STEMI patients undergoing immediate coronary catheterizationc unless there is a high risk of life-threatening bleeding or
other contraindications [23].
I B
Pre-treatment with a P2Y12 inhibitor is generally recommended in patients in whom coronary anatomy is known and the de-
cision to proceed to PCI is made as well as in patients with STEMI [20, 23, 38].
I A
In patients with NSTE-ACS undergoing invasive management, ticagrelor administration (180 mg loading dose, 90 mg twice
daily), or clopidogrel (600 mg loading dose, 75 mg daily dose) if ticagrelor is not an option, should be considered as soon as
the diagnosis is established.
IIa C
In patients with stable CAD, pre-treatment with clopidogrel may be considered if the probability of PCI is high. IIb C
Clopidogrel (600 mg loading dose, 75 mg daily dose) on top of aspirin is recommended in stable CAD patients undergoing
coronary stent implantation and in ACS patients who cannot receive ticagrelor or prasugrel, including those with prior intra-
cranial bleeding or indication for OAC [20, 23, 39, 40].
I A
Clopidogrel (300 mg loading dose in patients aged <_75, 75 mg daily dose) is recommended on top of aspirin in STEMI patients
receiving thrombolysis [31, 32].
I A
Ticagrelor or prasugrel on top of aspirin may be considered instead of clopidogrel in stable CAD patients undergoing PCI, tak-
ing into account the ischaemic (e.g. high SYNTAX score, prior stent thrombosis, location and number of implanted stents)
and bleeding (e.g. according to PRECISE-DAPT score) risks.
IIb C
In NSTE-ACS patients in whom coronary anatomy is not known, it is not recommended to administer prasugrel [25]. III B
ACS: acute coronary syndrome; CAD: coronary artery disease; DAPT: dual antiplatelet therapy; NSTE-ACS: non-ST-elevation acute coronary syndrome; OAC:
oral anticoagulant; PCI: percutaneous coronary intervention; PRECISE-DAPT: PREdicting bleeding Complications In patients undergoing Stent implant-
ation and subsEquent Dual Anti Platelet Therapy; STEMI: ST-elevation myocardial infarction; SYNTAX: Synergy Between Percutaneous Coronary Intervention
With Taxus and Cardiac Surgery.
aClass of recommendation.
bLevel of evidence.
cContraindications for ticagrelor: previous intracranial haemorrhage or ongoing bleeds. Contraindications for prasugrel: previous intracranial haemorrhage,
previous ischaemic stroke or transient ischaemic attack, or ongoing bleeds; prasugrel is not recommended for patients >_75 years of age or with a body weight
<60 kg.
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The value of ticagrelor beyond 12 months of therapy in pa-
tients with prior ACS has been investigated in the Prevention of
Cardiovascular Events in Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background of Aspirin–
Thrombolysis in Myocardial Infarction (PEGASUS) trial, which is
described in Chapter 4 [29].
P2Y12 inhibitors in STEMI patients treated with lysis: Clopidogrel is
the only P2Y12 inhibitor that has been properly investigated in pa-
tients with STEMI undergoing initial treatment with thrombolysis
[31, 32]. Clopidogrel 300 mg loading dose has been investigated
only in patients <_75 years of age [31]. While not specifically investi-
gating the value of clopidogrel, in the STrategic Reperfusion Early
After Myocardial Infarction (STREAM) study, patients aged 75 or
more received clopidogrel treatment without loading dose (i.e. initi-
ated at 75 mg q.d.) in association with half dose of lytic therapy
[30]. Hence, the administration of a clopidogrel loading dose in eld-
erly patients requires a patient-by-patient decision. While prasugrel
[33] or ticagrelor [20] were allowed as per protocol in patients with
prior treatment with lysis in P2Y12 inhibitor-naı̈ve patients or those
with prior clopidogrel administration, respectively, there are insuffi-
cient safety data to recommend their concomitant use during or
soon after thrombolysis.
Timing of initiation of P2Y12 inhibitor: The evidence (and lack
thereof) on optimal timing for the initiation of P2Y12 inhibitors
has been extensively discussed in previous guidelines [34] and re-
viewed elsewhere [35, 36]. A reasonable approach is to start
treatment with a P2Y12 inhibitor based on the timing with which
the drug was investigated in approval studies (i.e. start as soon as
possible and deemed safe for clopidogrel and ticagrelor or after
the indication for PCI is established based on coronary anatomy
for prasugrel). The decision to withhold early administration of
P2Y12 inhibitors may also depend on planned use of cangrelor in
the catheterization laboratory, which ensures immediate inhib-
ition of the target receptor in oral P2Y12 inhibitor-naı̈ve patients.
Timing of administration of P2Y12 inhibitors in patients receiving
cangrelor infusion at the time of PCI should be drug-specific [37].
While ticagrelor can be given any time before, during or at the
end of cangrelor infusion, it is recommended that clopidogrel or
prasugrel is given at the time of cangrelor infusion discontinu-
ation (or within 30 minutes before the end of infusion in the case
of prasugrel administration) [37]. However, the comparative effi-
cacy and safety of routine early oral P2Y12 inhibitor administra-
tion vs. the use of cangrelor in the catheterization laboratory in
patients with ACS undergoing invasive management deserves fur-
ther investigation. If coronary anatomy is known or the probabil-
ity of PCI is high (such as for STEMI patients), there is evidence
and general consensus that early administration of oral P2Y12 in-
hibitors outweighs any potential risks. On the other hand, there
are no convincing data that the benefits of early administration
of a P2Y12 inhibitor outweigh the possible risks in stable CAD pa-
tients undergoing diagnostic angiography.
3.7 Measures to minimize bleeding while on dual
antiplatelet therapy
Bleeding events after successful PCI are independently associated
with increased mortality and morbidity and this association is
likely causal [41, 42]. Therefore, every effort should be made to
minimize bleeding. Individualization of therapy is a key measure
and includes the identification of risk factors for bleeding, radial
access site, dosing of therapies, use of proton pump inhibitors
(PPIs), and appropriate selection of P2Y12 inhibitors.
Vascular access site: The Minimizing Adverse Haemorrhagic
Events by Transradial Access Site and Systemic Implementation of
angioX (MATRIX) trial is the most contemporary and largest trial on
access site selection where 8404 ACS patients were randomly allo-
cated to radial or femoral access [43]. The first co-primary outcome
of 30-day MACE—defined as death, MI, or stroke—occurred in 8.8%
of patients with radial access and 10.3% of patients with femoral ac-
cess [relative risk (RR) 0.85, 95% CI 0.74–0.99; two-sided P = 0.031;
formally non-significant at the pre-specified a of 0.025]. The second
co-primary outcome of 30-day net adverse clinical events (NACE)
[MACE or non-CABG BARC (Bleeding Academic Research
Consortium) major bleeding] was experienced in 9.8% and 11.7%
of patients, respectively (RR 0.83, 95% CI 0.73–0.96; P = 0.009).
Radial access was associated with a lower risk of all-cause mortality
(1.6% vs. 2.2%; RR 0.72, 95% CI 0.53–0.99; P = 0.045). Major BARC 3
or 5 bleeding was significantly reduced in the radial group (1.6% vs.
2.3%; RR 0.67, 95% CI 0.49–0.92; P = 0.013). Radial access was asso-
ciated with significantly lower rates of surgical access site repair or
transfusion of blood products. An updated meta-analysis including
MATRIX found a significant reduction in major bleeds; death, MI,
or stroke; and in all-cause mortality associated with radial as com-
pared to femoral access [44].
Aspirin dosing in patients treated with DAPT: Lower aspirin
doses (<_100 mg daily) have been consistently demonstrated to be
associated with less major and total bleeding than higher doses,
either when used as monotherapy or when combined with the
P2Y12 inhibitor clopidogrel [45–52]. This is because daily aspirin
doses as low as 30–50 mg are able to completely inactivate the
platelet cyclooxygenase-1 enzyme and inhibit thromboxane pro-
duction [53, 54]. In addition, the efficacy of ticagrelor may be
decreased in patients treated with higher aspirin doses (>_300 mg
daily) vs. lower aspirin doses (<_100 mg daily) [55]. Although the
molecular mechanism behind this finding is not entirely clear, it
reinforces the use of low dose aspirin. The optimal range of as-
pirin dose in patients treated with DAPT that provides maximal
protection from ischaemic events and minimizes bleeding risk
appears to be 75–100 mg.
Platelet function testing, genetic testing, and switching of P2Y12
inhibitors: High and low platelet reactivity on P2Y12 antagonist
treatment predicts ischaemic and bleeding risks, respectively [56].
These data have led to the rationale for individualized antiplatelet
therapy based on platelet function monitoring to identify the pa-
tients out of the expected range of platelet inhibition [57]. All
randomized trials have failed to demonstrate any benefit of
platelet function monitoring to adjust therapy [58–60]. The low-
risk level of the study populations, the exclusive use of clopidog-
rel, and the P2Y12 reaction unit thresholds to define the optimal
window of P2Y12 inhibition have been recognized as the main
limitations of these trials [61–63].
The Platelet Function Monitoring to Adjust Antiplatelet
Therapy in Elderly Patients Stented for an Acute Coronary
Syndrome (ANTARCTIC) trial has re-evaluated the concept of
individualized antiplatelet therapy by selecting only ACS patients
at high risk of both ischaemic and bleeding events (based on age
>_75 years) and more accurate thresholds in reflecting optimal
P2Y12 inhibition. Clopidogrel was replaced by prasugrel using the
recommended daily dose of 5 mg for the elderly, with the possi-
bility of adjustment up and down according to individual re-
sponse. Platelet function monitoring performed 14 days after
discharge and later if needed led to a change of treatment in
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45% of patients who were identified as being overtreated or
undertreated by measurement of the P2Y12 inhibition level; how-
ever, this strategy did not improve ischaemic or safety outcomes
[64]. The influence of genetic variants on the response to antipla-
telet agents, especially clopidogrel, has been well-established in
patients with ACS and planned PCI [65]. Rapidly-obtained genetic
information on the 2C19 genotype can help in reaching the opti-
mal window of P2Y12 inhibition according to the cytochrome
P450 (CYP) 2C19 profile [66, 67], but no randomized trial has
ever demonstrated any clinical benefit of such an approach.
Moreover, only 6–12% of the variability in on-clopidogrel plate-
let reactivity can be explained by the differences in genotype
[68, 69].
For these reasons, neither platelet function testing nor genetic
testing can be recommended for tailoring DAPT. It may be con-
sidered in specific situations (e.g. patients suffering from recur-
rent adverse events) if the results may change the treatment
strategy. This is the case for patients undergoing CABG who are
exposed to DAPT (see Chapter 5).
Proton pump inhibitors and DAPT: Gastrointestinal haemor-
rhage is the most common serious bleeding complication from
the use of long-term antiplatelet therapy [70]. RCTs have shown
that PPIs reduce the rate of recurrent gastrointestinal bleeding
in high-risk patients receiving aspirin [71]. Similar data exist
regarding the use of famotidine, a histamine H2-receptor antag-
onist [72].
Clopidogrel requires metabolic transformation in the liver by
CYP isoenzymes (mainly CYP2C19) to elicit its antiplatelet effect.
PPIs are also metabolized by CYP enzymes, leading to a potential
inhibition of CYP2C19 (mainly omeprazole and esomeprazole)
translating into reduced metabolic activation of clopidogrel when
taken together. Pharmacodynamic studies demonstrated the re-
duction of clopidogrel-induced antiplatelet effects when a PPI,
mainly omeprazole, was concomitantly administered [73–76].
Based on drug–drug interaction studies, omeprazole and esome-
prazole would appear to have the highest propensity for clinically
relevant interactions, lansoprazole an intermediate probability,
while pantoprazole and rabeprazole have the lowest [77].
However, importantly, no interaction between concomitant use of
PPIs and prasugrel or ticagrelor has been observed.
Only observational studies suggested an increased risk of car-
diovascular ischaemic events when PPI therapy was administered
concomitantly with clopidogrel [78]. Conversely, randomized tri-
als and propensity score-matched studies did not support such
concerns [76, 79–81].
The Clopidogrel and the Optimization of Gastrointestinal
Events Trial (COGENT) was a randomized, double-blind,
double-dummy, placebo-controlled, phase III study of the effi-
cacy and safety of a fixed-dose combination of clopidogrel
(75 mg) and omeprazole (20 mg), as compared with clopidogrel
alone [79]. Patients were eligible if they were 21 years of age or
older and if the use of clopidogrel therapy with concomitant as-
pirin was anticipated for at least the next 12 months, including
patients presenting with an ACS or undergoing placement of a
coronary stent. Patients at high risk for gastrointestinal bleeding
were excluded (i.e. those in whom the need for a PPI, an H2-
receptor antagonist, sucralfate, or misoprostol was anticipated;
with pre-existing erosive oesophagitis or oesophageal or gastric
variceal disease or previous non-endoscopic gastric surgery; re-
ceipt of oral anticoagulation therapy that could not be safely
discontinued for the duration of the study; or recent fibrinolytic
therapy). Therefore, following previous evidence of benefit from
a PPI or H2-receptor antagonist in high-risk patients treated
with aspirin monotherapy, the COGENT study included patients
at low risk of gastrointestinal bleeding undergoing DAPT, under
the rationale that the risk of gastrointestinal bleeding is higher
in patients taking aspirin and clopidogrel as compared to as-
pirin alone. This study was prematurely stopped with a total of
3761 patients instead of the planned 5000 due to financial rea-
sons. The pre-specified primary gastrointestinal efficacy end-
point was the time from randomization to the first occurrence
of a composite of upper gastrointestinal clinical events, which
occurred in 1.1% of patients with omeprazole and 2.9%
with placebo at 180 days after randomization (HR 0.34, 95% CI
0.18–0.63; P < 0.001) [79].
Furthermore, there was no significant increase in the risk of car-
diovascular events with concomitant use of clopidogrel and ome-
prazole (4.9%, 95% CI 3.4–6.4%, in the omeprazole group; and 5.7%,
95% CI 4.0–7.3%, in the placebo group; P = 0.98), a finding that was
consistent even in high-risk subgroups and for individual endpoints.
The rate of serious adverse events did not differ significantly be-
tween the two groups (10.1% with omeprazole and 9.4% with pla-
cebo, P = 0.48), nor did the rate of overall adverse events (41.3 and
42.8%, respectively; P = 0.33). Diarrhoea was reported in 3.0% of pa-
tients receiving omeprazole, as compared with 1.8% of those receiv-
ing placebo (P = 0.01). There were no newly diagnosed cases of
osteoporosis. One case of peripheral neuropathy was reported in
the placebo group.
No randomized data comparing use vs. non-use of PPI in pa-
tients taking aspirin and prasugrel or ticagrelor exist. However, the
risk of gastrointestinal bleeding is higher with DAPT in the form of
prasugrel [23] or ticagrelor [82] as compared to clopidogrel. The
short- and long-term safety profile of PPIs has been well-
established [79]. Impaired magnesium absorption with PPIs has
been reported only from studies in which patients had received a
PPI for at least 1 year [83]. Magnesaemia monitoring is recom-
mended at follow-up, especially for longer than 1 year of therapy.
Type, dose of P2Y12 inhibitor, and duration of treatment: The
type and dose of P2Y12 inhibitor are well-established according
to the various settings of CAD. Previous intracranial haemorrhage
or ongoing bleeds are common contraindications for prasugrel
and ticagrelor, while prasugrel should be given with caution in
patients >_75 years of age or with a body weight <60 kg. Patients
with previous stroke or transient ischaemic attack (TIA) may de-
rive harm from prasugrel instead of clopidogrel [23]. Prior stroke
is a marker of frailty and of subsequent risk of haemorrhagic
stroke, especially during the first year thereafter. Switching from
prasugrel or ticagrelor to clopidogrel is a common practice, espe-
cially in cases of minor bleeding or in patients with low platelet
reactivity, a marker of major bleeding risk [56, 84, 85]. There are
no properly powered randomized data on the long-term safety
or efficacy of ‘switching’ patients treated for weeks or months
with a P2Y12 inhibitor to a different P2Y12 inhibitor. Therefore,
this practice is generally discouraged.
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3.8 Switching between oral P2Y12 inhibitors
Differences in the pharmacology of P2Y12 receptor inhibitors
with regard to their binding site, half-life, and speed of onset and
offset of action are important factors that might lead to drug
interactions when switching from one agent to another.
The transition from clopidogrel to ticagrelor is the only switch
between P2Y12 inhibitors that has been investigated in a trial pow-
ered for clinical endpoint, even if the study was not specifically de-
signed to assess the safety and efficacy of the transition from
clopidogrel to ticagrelor. In PLATO, nearly 50% of patients ran-
domly allocated to receive ticagrelor had been pre-treated with
clopidogrel, mostly given as a 300–600 mg loading dose [20]. The
efficacy and safety of ticagrelor were not affected by previous clo-
pidogrel exposure [88]. On the other hand, the TRITON-TIMI 38
trial mandated that previous exposure of patients to a P2Y12 re-
ceptor inhibitor should be an exclusion criterion for study entry
[23]. While registry data provide reassuring information with respect
to the safety profile of switching from clopidogrel to prasugrel [89–
91], no randomized data exist in the setting of studies powered
for clinical endpoint. Similarly, all other switching possibilities,
including between prasugrel and ticagrelor or from ticagrelor/
prasugrel to clopidogrel, have not been investigated with out-
come data [92–94]. This practice is therefore discouraged due to
a lack of safety/efficacy data. As the need to switch between
P2Y12 inhibitors may arise for clinical reasons (i.e. side effects or
drug intolerance), and registry data indicate that switching is not
infrequent in practice, switching algorithms based on pharmaco-
dynamic studies are provided (Figure 2).
4. DUAL ANTIPLATELET THERAPY AND
PERCUTANEOUS CORONARY INTERVENTION
An overview of all studies investigating the benefits and risks
of DAPT duration beyond 1 month, largely focusing on post-
PCI patients or those with prior ACS, is shown in Web addenda
Table S1 (A and 1B). An overview of recommendations endorsed
by these guidelines regarding DAPT duration after PCI, as well as
after CABG or in medically managed ACS patients, is provided in
Figure 3.
4.1 Dual antiplatelet therapy after percutaneous
coronary intervention for stable coronary artery
disease
DAPT is not indicated in purely medically managed patients (i.e.
without prior PCI) with stable CAD and no history of prior MI.
The Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance (CHARISMA) study
included patients with stable vascular disease or at risk of athero-
thrombotic events, and showed that clopidogrel plus aspirin was
not significantly more effective than aspirin alone in reducing the
rate of MI, stroke, or death from cardiovascular causes [95].
After PCI with stent placement, DAPT is the standard of care. The
Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial [2]
and, subsequently, other studies [96, 97] established the 1-month
course of DAPT after bare-metal stent (BMS). An arbitrary 12-month
or more DAPT duration has been subsequently recommended
Measures to minimize bleeding while on dual antiplatelet therapy
Recommendations Classa Levelb
Radial over femoral access is recommended for coronary angiography and PCI if performed by an expert radial operator [43, 44]. I A
In patients treated with DAPT, a daily aspirin dose of 75–100 mg is recommended [45, 47, 51, 52]. I A
A PPI in combination with DAPTc is recommended [70, 79, 80, 86, 87]. I B
Routine platelet function testing to adjust antiplatelet therapy before or after elective stenting is not recommended [58–60]. III A
DAPT: dual antiplatelet therapy; PCI: percutaneous coronary intervention; PPI: proton pump inhibitor.
aClass of recommendation.
bLevel of evidence.
cWhile the evidence that a PPI does not increase the risk of cardiovascular events was generated with omeprazole, based on drug–drug interaction studies,
omeprazole and esomeprazole would appear to have the highest propensity for clinically relevant interactions, while pantoprazole and rabeprazole have the
lowest.
Switching between oral P2Y12 inhibitors
Recommendations Classa Levelb
In patients with ACS who were previously
exposed to clopidogrel, switching from clo-
pidogrel to ticagrelor is recommended early
after hospital admission at a loading dose of
180 mg irrespective of timing and loading
dosec of clopidogrel, unless contraindica-
tions to ticagrelor exist [20].
I B
Additional switching between oral P2Y12
inhibitors may be considered in cases of
side effects/drug intolerance according
to the proposed algorithms.
IIb C
ACS: acute coronary syndrome.
aClass of recommendation.
bLevel of evidence.
cContraindications for ticagrelor: previous intracranial haemorrhage or
ongoing bleeds.
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based on expert opinions after first generation DES, irrespective of
clinical presentation.
No dedicated study exists focusing on stable CAD patients
undergoing PCI and being exposed to different DAPT durations.
Hence, recommendations regarding stable CAD patients
undergoing PCI derive from subgroup analyses from pertinent
RCTs (Figure 4) [98, 99].
While no RCTs investigating the use of ticagrelor or prasugrel in-
stead of clopidogrel in stable CAD patients undergoing PCI exist, this
treatment option may be considered in selected patients in whom
the use of clopidogrel is unsatisfactory based on prior clinical out-
comes or potentially associated with higher risk of ischaemic events
that bleeding recurrences.
Three- or 6- vs. at least 12-month DAPT duration: The Efficacy
of Xience/Promus Versus Cypher to Reduce Late Loss After
Stenting (EXCELLENT) trial compared a 6-month DAPT [acetyl-
salicylic acid (ASA) + clopidogrel] duration with 1-year DAPT
after DES [100]. With 1443 patients randomized, the rates of tar-
get vessel failure—defined as the composite of cardiac death,
MI, or ischaemia-driven target vessel revascularization—at
12 months were 4.8% in the 6-month DAPT group and 4.3% in
the 12-month DAPT group (P = 0.001 for non-inferiority). There
was a numerically lower risk of bleeding in the short DAPT arm
(HR 0.50, 95% CI 0.09–2.73). There was no signal of heterogen-
eity for the primary study endpoint with respect to clinical pres-
entation (i.e. stable CAD, n = 699 patients vs. ACS, n = 744
patients). The PROlonging Dual antiplatelet treatment after
Grading stent-induced intimal hYperplasia (PRODIGY) trial
randomized 2013 patients [101] to 6 or 24 months of DAPT
(ASA + clopidogrel) and to one of four stent types (a four-by-
Ticagrelor MD (90 mg b.i.d.)
24h after last Clopidogrel dose
Figure 2: Algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting. LD: loading dose; MD: maintenance dose. Colour-coding refers to
the ESC Classes of Recommendations (green = Class I; orange: = Class IIb). The green arrow from clopidogrel to ticagrelor highlights the only switching algorithm for
which outcome data are available in patients with acute coronary syndrome. No outcome data (orange arrows) are available for all other switching algorithms. Acute
setting is considered as a switching occurring during hospitalization.
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Figure 4: Algorithm for dual antiplatelet therapy (DAPT) in patients treated with percutaneous coronary intervention. ACS: acute coronary syndrome; BMS: bare-
metal stent; BRS: bioresorbable vascular scaffold; CABG: coronary artery bypass graft surgery; DCB: drug-coated balloon; DES: drug-eluting stent; PCI: percutaneous
coronary intervention; Stable CAD: stable coronary artery disease.
High bleeding risk is considered as an increased risk of spontaneous bleeding during DAPT (e.g. PRECISE-DAPT score >_25).
Colour-coding refers to the ESC Classes of Recommendations (green = Class I; yellow = IIa; orange = Class IIb).
Treatments presented within the same line are sorted in alphabetic order, no preferential recommendation unless clearly stated otherwise.
1After PCI with DCB 6 months DAPT should be considered (Class IIa B).
2If patient presents with Stable CAD or, in case of ACS, is not eligible for a treatment with prasugrel or ticagrelor.
3If patient is not eligible for a treatment with prasugrel or ticagrelor.
4If patient is not eligible for a treatment with ticagrelor.
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two factorial design), including BMS and three different DES
types. The 2-year incidence of all-cause death, MI, and stroke
or cerebrovascular accident was 10.1% with 24-month DAPT
compared with 10.0% with 6-month DAPT (P = 0.91). There was
a lower risk of major bleeding with shorter DAPT based on both
the BARC (1.9% vs. 3.4%; HR 0.56, 95% CI 0.32–0.98; P = 0.037)
or the TIMI scale (0.6% vs. 1.6%; HR 0.38, 95% CI 0.15–0.97; P =
0.041). After censoring events that occurred after 12 months,
while keeping the original randomization design, the risk of
TIMI major bleeding was 0.5% in the short-term DAPT arm vs.
0.9% in the long-term DAPT arm (HR 0.56, 95% CI 0.19–1.66). In
this trial, a total of 1465 (74.3%) patients presented with ACS
whereas 505 (25.7%) had stable CAD [99]. No heterogeneity was
noted with respect to the primary efficacy endpoint. There was
a borderline quantitative interaction between clinical presenta-
tions and bleeding outcomes (P values for interaction = 0.056
for BARC 2, 3, or 5; P = 0.091 for BARC 3 or 5), suggesting a
higher hazard of bleeding in the 24-month DAPT arm when
compared with the 6-month arm in the stable CAD patients,
which was not observed in the ACS patients [99]. Analysis of
NACE—consisting of death, MI, cerebrovascular accident, or
BARC 2, 3, or 5 bleeding—revealed significant harm from ex-
tended DAPT in stable CAD patients (NACE in the 24-month vs.
6-month DAPT arm: 13.3% vs. 5.6%; HR 2.5, 95% CI 1.35–4.69, P
= 0.004; NNT for harm = 13) and no benefit in the ACS popula-
tion (16.1% vs. 14.1%; HR 1.15, 95% CI 0.88–1.50; P = 0.29), with
positive quantitative interaction testing (P value for interaction
= 0.024) [99]. Patients with high CRUSADE (Can Rapid risk strati-
fication of Unstable angina patients Suppress ADverse outcomes
with Early implementation of the ACC/AHA Guidelines) bleed-
ing risk score treated with 24-month DAPT experienced a three-
fold higher risk of major bleeding and a fivefold risk of red
blood cell transfusion as compared with 6-month therapy, with-
out clear evidence of benefit [13].
In 2014, three additional randomized studies were published
that compared 6 months of DAPT to 12 or 24 months of DAPT
(ASA + clopidogrel): Is There a Life for DES After Discontinuation
of Clopidogrel (ITALIC) [102], Second Generation Drug-Eluting
Stent Implantation Followed by Six- Versus Twelve-Month Dual
Antiplatelet Therapy (SECURITY) [103], and Intracoronary
Stenting and Antithrombotic Regimen: Safety and Efficacy of
6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting
(ISAR-SAFE) [104]. ISAR-SAFE was the largest of these three stud-
ies, with 4005 randomized patients, and the only double-blind
investigation. It confirmed that a 12-month course of DAPT did
not afford any benefit over a 6-month course with respect to is-
chaemic endpoints. Likewise, the net clinical benefit (composite
of death, MI, stent thrombosis, stroke, and TIMI major bleeding)
was neutral. At subgroup analysis, there was no signal of hetero-
geneity with respect to the primary study endpoint among the
2394 patients who presented with stable CAD as opposed to the
1601 patients with ACS [104]. Consistent results were shown in
the ITALIC and SECURITY trials. Two studies, Real Safety and
Efficacy of 3-Month Dual Antiplatelet Therapy Following
Endeavor Zotarolimus-Eluting Stent Implantation (RESET) [105]
and Optimized Duration of Clopidogrel Therapy Following
Treatment With the Zotarolimus-Eluting Stent in Real-World
Clinical Practice (OPTIMIZE) [106], investigated a 3-month dur-
ation of DAPT (ASA + clopidogrel). RESET randomized 2117 pa-
tients to 3- or 12-month duration of DAPT and did not show
significant harm with the shortened period (composite rates of
any death, MI, or stent thrombosis 0.8% vs. 1.3%; P = 0.48).
Similar results were achieved in OPTIMIZE with 3119 patients
randomized. In this study, the 1-year incidence of MACE was
8.3% in the short-term group and 7.4% in the long-term group
(HR 1.12, 95% CI 0.87–1.45). Both studies mandated the use of
the Endeavor zotarolimus-eluting stent (ZES) in the 3-month
DAPT arms, which is no longer available on the market. It is not
clear to what extent the results of RESET and OPTIMIZE are ap-
plicable to other types of DES.
Palmerini et al. performed a meta-analysis addressing the out-
come of a <_6-month course of DAPT vs. a 1-year course after
DES [107]. The 1-year course of therapy did not confer any ad-
vantage over the shorter course of DAPT with respect to survival,
stent thrombosis, or MI, but it increased the risk of major bleed-
ing substantially. Similar results were obtained by other meta-
analyses [108, 109].
Twelve-month vs. >12-month DAPT duration: Following the
proposed landmark of 12 months as the standard DAPT dur-
ation after DES, the DAPT trial investigated whether further ex-
tension of DAPT might be beneficial [110]. The DAPT study
enrolled patients who, at 12 months after placement of a DES,
were still on DAPT and had not suffered an ischaemic or bleed-
ing event. Patients were randomly allocated to thienopyridine
or placebo for another 18 months. Aspirin was maintained
throughout the study period. Thirty-month DAPT as compared
with 12-month DAPT reduced the rates of stent thrombosis
(0.4% vs. 1.4%; P < 0.001) and of major adverse cardiac and
cerebrovascular events (MACCE) (4.3% vs. 5.9%; P < 0.001). This
included a substantial reduction in the rate of MI (2.1% vs. 4.1%;
P < 0.001); slightly more than half of this benefit could be attrib-
uted to the prevention of spontaneous MIs (see chapter 3.2).
This ischaemic protection came at the cost of an increased risk
of bleeding (GUSTO moderate or severe bleeding 2.5% vs. 1.6%,
P < 0.001) and an increase in total mortality with borderline
statistical significance (see section 3.3).
Of 11 648 randomized patients within the DAPT trial (9961
treated with DES and 1687 with BMS), 30.7% presented with MI
[98]. The excess of mortality observed within the 30-month DAPT
arm was entirely driven by fatalities, which occurred in patients
without prior MI (2.1% for continued thienopyridine group vs.
1.5% for placebo; HR 1.43, 95% CI 1.02–2.00; P = 0.04). Yet, the
interaction P value did not reach statistical significance (effect for
MI vs. no MI interaction P = 0.13) [99].
Three independent meta-analyses, which included 5045 pa-
tients recruited within DES-Late coronary Arterial Thrombotic
Events (LATE) [111] and 1259 patients from the Assessment by a
Double Randomisation of a Conventional Antiplatelet Strategy
Versus a Monitoring-Guided Strategy for Drug-Eluting Stent
Implantation and, of Treatment Interruption Versus Continuation
1 Year After Stenting-Interruption (ARCTIC-Interruption) trial
[112], provided results consistent with a possible increase in mor-
tality with prolonged DAPT as shown in the DAPT trial. A more
recent meta-analysis of 11 RCTs that enrolled 33 051 patients
who received predominantly newer-generation DES also pro-
vided weak evidence of an increased mortality rate with pro-
longed DAPT [113].
Thus, if DAPT is administered for a sufficient length of time
after placement of DES for stable CAD, a substantial benefit in
terms of secondary prevention and reduction of stent thrombosis
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emerges. However, this benefit is counterbalanced by an
increased risk of bleeding and by a signal for increased mortality.
Thus, systematic extension of DAPT beyond six months is not jus-
tified for all patients but should be based on the individual risk
profile of the patient (see section 3.5).
Impact of type of DES on duration of DAPT: The benefit of ex-
tended periods of DAPT varies with stent type. However, there
are differences between first- and newer-generation DES. In
PRODIGY, only patients with the paclitaxel-eluting stent benefit-
ted from extended DAPT with a significant reduction of the risk
of stent thrombosis [114]. Likewise, in DAPT, the benefit of ex-
tended DAPT was largest with patients with a paclitaxel-eluting
stent and the smallest with an everolimus-eluting stent [110, 115].
There also was a significant interaction between stent type and
benefit of extended DAPT with respect to MACCE [110]. With an
everolimus-eluting stent, the 1-year NNT for prevention of stent
thrombosis was 157, whereas the 1-year NNT for harm for mod-
erate or severe bleeding was 56 [115]. In the meta-analysis by
Giustino et al. [109], the reduction of stent thrombosis by ex-
tended DAPT was significantly reduced with new-generation
stents as compared with first-generation DES, and statistical sig-
nificance was lost within the new-generation subset. No such
interaction was found concerning bleeding complications.
Similar results were obtained in two other meta-analyses
(Sharma et al. [116] and Palmerini et al. [117]).
Bioresorbable stents and drug-coated balloons: No dedicated
studies examining the optimal duration of DAPT after implant-
ation of a bioresorbable scaffold currently exist. In the largest
randomized clinical trial investigating the treatment of patients
with a poly-lactic acid-based bioresorbable scaffold, DAPT was
recommended for at least 12 months [118]. However, meta-
analysis has shown evidence of an approximately twofold higher
rate of stent thrombosis in comparison with conventional DES,
especially in the first 30 days after implantation [119]. This pro-
vides a rationale for considering more potent P2Y12 inhibitors in
these patients. In addition, some concerns have been raised re-
garding late stent thrombosis beyond 1 year after implantation
[120, 121] and a longer duration of DAPT therapy may be advo-
cated, at least in patients at low bleeding risk. No large-scale
clinical trials are available concerning magnesium-based biore-
sorbable scaffolds.
In patients treated with drug-coated balloons, dedicated clinical
trials investigating the optimal duration of DAPT are lacking. In
patients treated for in-stent restenosis, the largest randomized tri-
als investigating drug-coated balloon therapy have recommended
a treatment duration of between 3–12 months [122–124]. In
addition, some small clinical trials, as well as larger registries,
including patients with stable CAD undergoing drug-coated bal-
loon angioplasty have recommended DAPT duration of at least
1 month [125].
Plain old balloon angioplasty: no data on DAPT or DAPT dur-
ation exist after plain old balloon angioplasty, which is currently
reserved for a small minority of patients in whom stent implant-
ation is not feasible (e.g. small calibre vessel or extreme vessel
tortuosity) or desirable (e.g. to avoid DAPT in patients referred
to CABG). The institution of DAPT and its duration, if imple-
mented, should depend on clinical profile (ischaemic vs. bleed-
ing risks) and/or the reasons (e.g. planned surgery) for avoiding
stent implantation.
4.2 Dual antiplatelet therapy after percutaneous
coronary intervention for acute coronary
syndrome
DAPT with novel P2Y12 inhibitors for 1 year after PCI for ACS: The
evidence supporting the value of the combination of aspirin and
clopidogrel in patients with ACS has been extensively reviewed in
Dual antiplatelet therapy duration and related stent
choices in patients with stable coronary artery disease
treated with percutaneous coronary intervention
Recommendations Classa Levelb
In patients with stable CAD treated with cor-
onary stent implantation, DAPT consisting of
clopidogrel in addition to aspirin is generally
recommendedc for 6 months, irrespective of
the stent type [100, 101, 104, 126–130].
I A
Irrespective of the intended DAPT duration,
DESc is the preferred treatment option [129–
132].
I A
In patients with stable CAD considered at high
bleeding risk (e.g. PRECISE-DAPT >_25), DAPT
for 3 monthsd should be considered [105, 106].
IIa B
In patients with stable CAD treated with
drug-coated balloon, DAPT for 6 months
should be considered [122, 124, 133].
IIa B
In patients with stable CAD treated with bio-
resorbable vascular scaffolds, DAPT for at
least 12 months should be considered.
IIa C
In patients with stable CAD who have toler-
ated DAPT without a bleeding complication
and who are at low bleeding but high throm-
botic risk, continuation of DAPT with clopi-
dogrel for >6 months and <_30 months may
be considered [26, 107–109].
IIb A
In patients with stable CAD in whom 3-
month DAPT poses safety concerns, DAPT
for 1 monthe may be considered.
IIb C
BMS: bare-metal stent; CAD: coronary artery disease; DAPT: dual anti-
platelet therapy; DES: drug-eluting stent; MI: myocardial infarction;
PRECISE-DAPT: PREdicting bleeding Complications In patients
undergoing Stent implantation and subsEquent Dual Anti Platelet
Therapy.
aClass of recommendation.
bLevel of evidence.
cThese recommendations refer to stents that are supported by large-
scale randomized trials with clinical endpoint evaluation leading to un-
conditional CE mark, as detailed in Byrne et al. [134].
dThe evidence supporting this recommendation comes from two stud-
ies where zotarolimus-eluting Endeavour sprint stent has been investi-
gated in conjunction with a 3-month DAPT regimen.
e1-month DAPT following implantation of zotarolimus-eluting Endeavour
sprint stent or drug-coated stent reduced risks of re-intervention, myocar-
dial infarction and inconsistently of stent thrombosis compared to bare-
metal stent under similar DAPT duration [129, 130]. It is unclear if this evi-
dence applies to other contemporary DES.
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previous guidelines (NSTE-ACS), and data supporting the super-
iority of ticagrelor and prasugrel over clopidogrel in this setting
are discussed in section 3.6.
Although both prasugrel and ticagrelor significantly increase
the risk of TIMI major non-CABG related bleeds, the risk–benefit
ratios were favourable with NNT for benefit of 46 and 53, re-
spectively, and NNT for harm of 167 for both agents. These data
established the 1-year course of DAPT, preferably with prasugrel
or ticagrelor, for patients undergoing PCI for ACS, unless there
are contraindications (Figure 4).
Mounting evidence for secondary prevention by intensified anti-
platelet therapy: In patients presenting with ACS, the cardiovascu-
lar risk remains substantially elevated beyond the first year, even
if successful revascularization has been achieved. In this setting,
intensified antiplatelet therapy on top of aspirin has been shown
to be an effective therapeutic strategy to prevent recurrent is-
chaemic events. However, the risk–benefit ratios seem less fa-
vourable than those observed in studies assessing <_1-year DAPT
duration. Relevant information has been provided by the prior
MI patient subsets included in the CHARISMA [135] (n = 3846)
and DAPT [98] (n = 3576) trials, which mainly compared clopi-
dogrel with placebo on top of aspirin; by the subset of patients
who underwent coronary angiography within the TRILOGY [136]
trial, which compared prasugrel with clopidogrel; and by the pa-
tients with prior MI within the Thrombin Receptor Antagonist in
Secondary Prevention of Atherothrombotic Ischemic Events (TRA
2P-TIMI 50) [137] (n = 17 779 ) trial, which compared vorapaxar
with placebo. Taken separately, these trial results are difficult to
interpret because they are based on subgroup analyses.
Moreover, CHARISMA and TRILOGY had a neutral main out-
come and the main results of TRA 2P-TIMI 50 showed an un-
favourable risk–benefit ratio. Therefore, a dedicated trial on
prolonged DAPT for secondary prevention after ACS was needed.
The PEGASUS trial filled this gap [29].
DAPT with ticagrelor for secondary prevention after MI:
PEGASUS recruited 21 162 patients with spontaneous MI 1–3
years before enrolment, who were at >_50 years old and had at
least one additional high-risk feature: age >_65 years, diabetes
mellitus, a second spontaneous MI, multivessel CAD, or chronic
renal dysfunction [29]. The patients were randomly assigned to
ticagrelor 90 mg b.i.d., ticagrelor 60 mg b.i.d., or placebo. All the
patients received low-dose aspirin. Of the patients included in
PEGASUS, 53% were enrolled after a STEMI and 83% were previ-
ously treated by PCI. The primary efficacy endpoint was the com-
posite of cardiovascular death, MI, or stroke at 3 years and was
7.85% in the 90 mg arm, 7.77% in the 60 mg arm, and 9.04% in
the placebo arm (P = 0.008 and P = 0.004 for the higher and
lower doses, respectively, vs. placebo) [29]. There was a consistent
reduction in all components of the primary endpoint with tica-
grelor vs. placebo, which reached statistical significance for MI
with both doses of ticagrelor and for stroke with the lower dose.
There was also a trend for a reduction in cardiovascular mortal-
ity. Due to a non-significant yet numerical increase in non-
cardiovascular deaths in the two ticagrelor arms, the outcome
was neutral with respect to all-cause death. The primary safety
endpoint of TIMI major bleeding was observed more frequently
with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than
with placebo (1.06%) (P < 0.001 for each dose vs. placebo). The
NNT for benefit for the primary endpoint was 250 for the 90 mg
dose and 238 for the 60 mg dose; the corresponding NNT for
harm was 244 and 322, respectively, with the two ticagrelor
doses [29].
With the 90 mg dose, the absolute benefit in terms of the pri-
mary efficacy endpoint was in the same order as the absolute
harm in terms of the primary safety endpoint, and with 60 mg
the absolute benefit was only marginally larger than the absolute
harm. However, the relevance of the various endpoints to the pa-
tient’s overall well-being may differ and are, therefore, difficult to
weigh against one another. The impact of MI and bleeding on
mortality was comparable in previous studies [11, 138]. A post
hoc analysis from the Thrombin Receptor Antagonist for Clinical
Event Reduction in Acute Coronary Syndrome (TRACER) trial sug-
gested that while bleeding according to BARC 2 and 3a criteria
was less prognostic for death than MI, the risk of mortality was
equivalent between BARC 3b bleeding and MI, and was higher
following BARC 3c bleeding. Moreover, at variance with previous
analyses, both MI and bleeding impacted mortality with similar
time dependency [42]. In view of these consistent findings
throughout multiple independent studies, both the efficacy and
the safety endpoints deserve attention, as both most likely simi-
larly impact mortality. With this background, the narrow risk–
benefit ratio cautions against the universal long-term administra-
tion of ticagrelor for secondary prevention after MI, and calls for
individualized treatment decisions based on ischaemic and
haemorrhagic risk.
To this end, patients who continued their thienopyridine treat-
ment without (a major) interruption (<_30 days) derived a larger
benefit from extended ticagrelor intake than patients who inter-
rupted their thienopyridine treatment for longer periods of time
[139]. Depending on the actual discontinuation time frame of
previous thienopyridine therapy, the HRs (95% CI) of the primary
endpoint for ticagrelor (pooled doses) vs. placebo were 0.73
(0.61–0.87) for those who continued within 30 days, 0.86 (0.71–
1.04) for those who interrupted for 30 days to 1 year, and 1.01
(0.80–1.27) for those who interrupted for more than 1 year (P
trend for interaction <0.001) [139]. There was no significant inter-
action of timing with the effect of ticagrelor on bleeding risk.
These findings suggest that patients who can continue their initial
thienopyridine treatment are those deriving relatively greater
benefit from DAPT continuation with ticagrelor. Nevertheless,
even in this patient subset, the absolute increase in TIMI major
bleeding associated with extended ticagrelor was similar in mag-
nitude as compared to the absolute decrease in the composite is-
chaemic endpoint (i.e. 1.9 percentage point difference for both
the safety and the efficacy endpoints) [139].
Patients with lower-extremities artery disease (LEAD), who are
known to be at greater ischaemic risk, also derived heightened
benefit from extended ticagrelor [140]. In these patients, the abso-
lute decreases in the primary efficacy endpoint achieved by tica-
grelor vs. placebo were 3.0% for the 90 mg dose and 5.2% for the
60 mg dose, whereas the increases in TIMI major bleeding were
only 0.22% and 0.02%, respectively. In addition, ticagrelor was sig-
nificantly associated with fewer events related to LEAD (i.e. acute
limb ischaemia and peripheral revascularization procedures).
DAPT with thienopyridines (clopidogrel or prasugrel) for second-
ary prevention after MI: In the DAPT trial, 3567 patients had ini-
tially presented with MI [98]. A non-prespecified analysis of these
patients investigated whether the benefits and risks of extended
vs. standard duration of DAPT was similar among patients with
or without MI. The active comparator was prasugrel in one-third
of the patients with MI and clopidogrel in two-thirds of the
patients.
In patients with MI, extended DAPT as compared with aspirin
alone reduced stent thrombosis significantly (0.5% vs. 1.9%;
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P < 0.001). There also was a significant reduction of MACCE by
extended DAPT (3.9% vs. 6.8%; P < 0.001). This included a major
reduction in the rate of recurrent MI (2.2% vs. 5.2%; P < 0.001).
On the other side, GUSTO moderate or severe bleeding was sig-
nificantly increased by extended DAPT (1.9% vs. 0.8%, P = 0.005).
Contrary to the main study, all-cause mortality was similar in the
extended DAPT group as compared with the placebo group
(1.4% vs. 1.6%; P = 0.61), even if formal interaction testing was
inconclusive.
A meta-analysis on the effect of extended DAPT in patients
with previous MI comprising PEGASUS and MI subgroups of
studies with thienopyridines—CHARISMA, PRODIGY, and DES-
LATE with clopidogrel as well as ARCTIC-Interruption and DAPT
with clopidogrel or prasugrel—has been recently published
[141]. Extended DAPT decreased the risk of MACCE compared
with aspirin alone (6.4% vs. 7.5%; P = 0.001). There was a con-
sistent significant reduction in each component of the primary
endpoint (RR 0.85, 95% CI 0.74–0.98 for cardiovascular death;
RR 0.70, 95% CI 0.55–0.88 for MI; RR 0.81, 95% CI 0.68–0.97 for
stroke). This benefit was achieved at the cost of a significantly
increased risk of major bleeding (1.85% vs. 1.09%; P = 0.004).
Although the reduction in cardiovascular mortality associated
with prolonged DAPT was significant, the absolute risk reduc-
tion was small (0.3%). In addition, there was no difference in all-
cause mortality (4.0% in the extended DAPT group and 4.2% in
the aspirin alone group). No significant difference between
study heterogeneity was identified across the appraised end-
points. This may suggest a consistent class effect among the
three P2Y12 inhibitors (clopidogrel, ticagrelor, or prasugrel).
However, caution should be used in interpreting this finding,
taking into account that the PEGASUS study alone contributed
>_60% to pooled endpoint estimates and that PEGASUS was the
only trial included in its totality (and as such the only properly
powered study for post-MI patients), whereas post hoc sub-
groups of patients recruited in the other four investigations
were pooled. In addition, when the overall included popula-
tions of the four available studies assessing DAPT for >1 year vs.
12-month therapy are pooled, an extended treatment with tica-
grelor, as compared to a similar strategy with thienopyridines,
exerted a more favourable effect on all-cause mortality due to a
trend towards reduction of cardiovascular death and a null ef-
fect on non-cardiovascular death [142]. Finally, PEGASUS was
the only trial that allowed patients who had stopped DAPT
months or years before to randomly restart therapy; this likely
resulted in relatively lower efficacy endpoint estimates as com-
pared to other studies testing duration of thienopyridines where
treatment was either permanently stopped or continued with-
out treatment interruptions in between. Therefore, it is reason-
able to favour ticagrelor 60 mg b.i.d. as the agent of choice for
prolonging DAPT beyond 12 months in stabilized post-MI pa-
tients at low bleeding risk, and to reserve the use of clopidogrel
(or prasugrel, the least investigated agent in this setting) as the
alternative choice if ticagrelor therapy is not tolerated or
feasible.
Shortening of DAPT duration in patients at high bleeding risk:
There is no dedicated RCT assessing the optimal DAPT duration
in patients at high bleeding risk. Moreover, many, if not all, avail-
able DAPT studies formally excluded these patients from inclu-
sion. The Zotarolimus-eluting Endeavor sprint stent in Uncertain
DES Candidates (ZEUS) and the Prospective randomized com-
parison of the BioFreedom biolimus A9 drug-coated stent versus
the gazelle BMS in patients at high bleeding risk (LEADERS-FREE)
studies recruited a selected high bleeding risk population and
randomized them to BMS or drug-coated stent under a
protocol-mandated DAPT duration of 1 month [129, 130]. Both
studies, as discussed in section 2.4, proved the superiority of the
investigated DES technologies as compared to BMS despite a
similarly short duration of DAPT. The trade-off between bleeding
prevention and ischaemic protection of prolonging DAPT be-
yond 1 month in this patient subset remains unclear.
Dual antiplatelet therapy duration in patients with acute coronary syndrome treated with percutaneous coronary
intervention
Recommendations Classa Levelb
In patients with ACS treated with coronary stent implantation, DAPT with a P2Y12 inhibitor on top of aspirin is recommended
for 12 months unless there are contraindications such as excessive risk of bleeding (e.g. PRECISE-DAPT >_25) [20, 23, 40].
I A
In patients with ACS and stent implantation who are at high risk of bleeding (e.g. PRECISE-DAPT >_25), discontinuation of
P2Y12 inhibitor therapy after 6 months should be considered [13, 18, 143].
IIa B
In patients with ACS treated with bioresorbable vascular scaffolds, DAPT for at least 12 months should be considered. IIa C
In patients with ACS who have tolerated DAPT without a bleeding complication, continuation of DAPT for longer than
12 months may be considered [26, 139].
IIb A
In patients with MI and high ischaemic riskc who have tolerated DAPT without a bleeding complication, ticagrelor 60 mg
b.i.d. for longer than 12 months on top of aspirin may be preferred over clopidogrel or prasugrel [29, 115, 142].
IIb B
ACS: acute coronary syndrome; b.i.d.: bis in die; DAPT: dual antiplatelet therapy. MI: myocardial infarction; PRECISE-DAPT: PREdicting bleeding Complications
In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy.
aClass of recommendation.
bLevel of evidence.
cDefined as >_ 50 years of age, and one or more of the following additional high-risk features: age of 65 years or older, diabetes mellitus requiring medication, a
second prior spontaneous myocardial infarction, multivessel coronary artery disease, or chronic renal dysfunction, defined as an estimated creatinine clear-
ance <60 ml/min.
These recommendations refer to stents that are supported by large-scale randomized trials with clinical endpoint evaluation leading to unconditional CE
mark, as detailed in Byrne et al. [134].
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As discussed in section 4.1, two studies compared 3- vs. 12-
month DAPT duration after DES. Patients were not selected
based on high bleeding risk criteria and both studies included
only a minority of patients presenting with acute MI (14.3 and
5.4% in the RESET and OPTIMIZE trials, respectively) [105, 106].
After an ACS, high bleeding risk status poses even greater
challenges with respect to the choice of DAPT duration. The risks
of shortening DAPT below 1 year have been addressed by an in-
dividual patient data meta-analysis [143]. This meta-analysis
comprised six trials comparing three- or six-month DAPT with
12-month DAPT including 11 473 patients, 4758 of whom had
ACS. In patients with ACS, shortening DAPT to <_ 6 months was
associated with an estimated increase in the risk of MI or defin-
ite/probable stent thrombosis from 1.7% to 2.4% compared with
1-year DAPT. Although this increase did not reach statistical sig-
nificance (HR 1.48, 95% CI 0.98–2.22; P = 0.059), it has to be
kept in mind that the power of this analysis was limited since
the number of patients with ACS included was roughly only
one-third or one-fourth of that in TRITON or PLATO, which es-
tablished the superiority of intensified antiplatelet therapy over
conventional 1-year DAPT with clopidogrel. Despite this limita-
tion, it is probably fair to conclude that the ischaemic risk of
shortening DAPT to 6 months after PCI in ACS is low, although
not negligible. In this respect, it is also reassuring that there was
no signal with respect to cardiac or all-cause death (HR 0.75,
95% CI 0.45–1.27 and HR 0.85, 95% CI 0.58–1.26, respectively).
Only when DAPT duration was reduced to 3 months did the risk
of MI and definite/probable stent thrombosis increase substan-
tially (HR 2.08, 95% CI 1.10–3.93). In summary, currently avail-
able evidence suggests considering discontinuation of P2Y12
inhibitor therapy after 6 months, when the risk of bleeding is
high.
4.3 Gaps in the evidence
With a marginal overall benefit-to-risk ratio of extended DAPT be-
yond 1 year after DES placement, tools to identify ideal candidates
for long-term or even indefinite DAPT duration are critically needed.
The DAPT score [15] as well as the subgroup analyses of PEGASUS
[139, 140, 144, 145] are important steps forward, but prospective val-
idation in contemporary cohorts of newer-generation DES patients is
needed.
The optimal level of platelet inhibition during the various
stages of CAD remains an open question. The risk of ischaemic
complication is highest immediately after PCI and then gradually
declines. The same is true for patients managed for ACS, although
the risk remains elevated above that of patients who never expe-
rienced an acute exacerbation for years. Thus, it is intuitive that
during the chronic phase after stabilization the level of platelet
inhibition may be reduced as compared with the acute phase.
Until recently, there were only limited data addressing this issue
from beyond the periprocedural phase to 1 year. By now, two
studies addressing such a step-down concept have finished re-
cruitment: Testing Responsiveness to Platelet Inhibition on
Chronic Antiplatelet Treatment For Acute Coronary Syndromes
Trial (TROPICAL-ACS) (NCT01959451) with a step-down from
prasugrel to clopidogrel after the peri-interventional phase in
acute MI; and GLOBAL-LEADERS (NCT01813435) [146] with a
step-down from DAPT to single antiplatelet therapy with ticagre-
lor beyond the first month after PCI in an all-comers cohort with
DES.
The risks and benefits of shortening DAPT to 3 months or even
shorter is another area with limited evidence. There are only two
randomized studies with a total of 5236 patients [105, 106]. Both
studies used the first-generation ZES that, due to its limited effi-
cacy in suppressing neointima formation, has been largely
replaced by a newer generation. Thus, in most cases with high
bleeding risk, the decision to shorten DAPT below 6 months needs
to rely on circumstantial evidence suggesting comparable safety of
different stent types.
As outlined in section 4.1, there are no dedicated studies on the
optimal duration of DAPT after the application of drug-eluting bal-
loons or after implantation of a bioresorbable scaffold. It is also un-
clear whether, early after placement of a bioresorbable stent, patients
may benefit from the more potent P2Y12 inhibition achieved by pra-
sugrel or ticagrelor as compared with the current practice of clopi-
dogrel administration.
5. DUAL ANTIPLATELET THERAPY AND CARDIAC
SURGERY
5.1 Dual antiplatelet therapy in patients treated
with coronary artery bypass surgery for stable
coronary artery disease
DAPT in ACS patients significantly reduces the risk of thrombotic
complications but increases the risk for both spontaneous and
surgical bleeding complications [20, 23, 40]. The bleeding risk as
well as the ischaemic benefit are further increased if ticagrelor or
prasugrel are used instead of clopidogrel [20, 23]. Unlike for ACS,
there is currently no evidence of a survival benefit or a reduction
of thromboembolic complications with DAPT in patients with
stable CAD undergoing CABG. However, there is limited evidence
suggesting that the use of DAPT in patients with stable CAD miti-
gates the risk of vein (but not arterial) graft occlusions.
5.2 Dual antiplatelet therapy in patients treated
with coronary artery bypass surgery for acute
coronary syndrome
Background: DAPT, as compared to aspirin monotherapy, has been
proven to be beneficial in reducing ischaemic risk in ACS patients
(Figure 5). However, there is limited evidence in patients undergoing
CABG as no dedicated study exists. In the Clopidogrel in Unstable
Angina to Prevent Recurrent Events (CURE) trial, the outcome in the
CABG subpopulation was consistent with the overall results of the
study [147]. Further support has been presented in two meta-
analyses [148, 149]. In the CABG substudies of the TRITON-TIMI 38
and the PLATO trials where, respectively, prasugrel and ticagrelor
were tested against clopidogrel in combination with ASA, both newer
P2Y12 inhibitors were more effective than clopidogrel in preventing
fatal outcomes, with a higher risk for bleeding in the former but not
the latter trial [150, 151].
Continuation of DAPT until CABG increases the risk of exces-
sive perioperative bleeding, transfusions, and re-exploration for
bleeding as shown in RCTs [147, 150, 151], observational studies
[152, 153], and meta-analyses [154, 155]. Therefore, it is recom-
mended that the P2Y12 inhibitor be discontinued whenever pos-
sible before elective CABG [156, 157]. Alternatively, elective
operations may be postponed until the DAPT treatment period is
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completed. In urgent cases, most often patients with ACS, the risk
of thrombotic episodes (stent thrombosis or MI) while waiting
for the effect of the P2Y12 inhibitor to cease must be weighed
against the risk of perioperative bleeding complications. In ex-
treme high-risk patients, e.g. those with recent DES implantation,
bridging therapy with cangrelor or a glycoprotein IIb/IIIa blocker
may be considered [156, 157].
P2Y12 inhibitors: The safe discontinuation interval varies between
the different P2Y12 inhibitors due to variations in platelet inhibitory
effect and pharmacodynamic and pharmacokinetic properties
[158]. For clopidogrel, it was shown in the CABG substudy of the
CURE trial that discontinuation >_5 days before CABG did not
increase the risk of bleeding complications [147]. For prasugrel, a
longer time interval (7 days) is recommended due to the longer
offset time compared to clopidogrel [158] and the high incidence
of CABG-related bleeding complications reported in the CABG
substudy of the TRITON-TIMI 38 trial [151]. In CABG patients
treated preoperatively with ticagrelor, 5 days of discontinuation
was initially recommended. This recommendation was based on
pharmacokinetic studies and clinical data from patients with stable
CAD [159]. However, recent data from large observational studies
in CABG patients challenge this recommendation [152, 153, 160].
In a Swedish nationwide study, CABG-related bleeding complica-
tions in patients treated with ticagrelor or clopidogrel were thor-
oughly investigated with respect to timing of P2Y12 inhibitor
discontinuation [152]. When either drug was discontinued accord-
ing to the instructions for use (>120 h before surgery), there was no
significant difference in the incidence of major bleeding complica-
tions between ticagrelor- and clopidogrel-treated patients (9% vs.
12%; unadjusted OR 0.72, 95% CI 0.51–1.02; P = 0.065). Within the
ticagrelor group, there was no significant difference in major bleed-
ing complications between discontinuation 72–120 h or >120 h
before surgery (OR 0.93, 95% CI 0.53–1.64; P = 0.80), whereas discon-
tinuation 0–72 h before surgery was associated with a significantly
higher rate of major bleeding compared with both 72–120 h (OR
5.17, 95% CI 2.89–9.27; P < 0.0001) and >120 h (OR 4.81, 95% CI
3.34–6.95; P < 0.0001). In contrast, clopidogrel-treated patients had a
higher incidence of major bleeding complications when discontinued
72–120 h compared with >120 h before surgery (OR 1.71, 95% CI
1.04–2.79; P = 0.033). Likewise, in the clopidogrel group, discontinu-
ation 0–72 h before surgery was associated with an increased inci-
dence of major bleeding compared with 72–120 h (OR 1.67, 95% CI
1.02–2.73; P = 0.042) and >120 h (OR 2.85, 95% CI 1.98–4.10; P <
0.0001) (Web Figure 2, see Web Addenda) [152]. Further support for
using 3 days as the discontinuation period in ticagrelor-treated pa-
tients comes from the PLATO trial, where a discontinuation period of
24–72 h was recommended. In a single institution Dutch registry en-
compassing 705 consecutive patients who underwent isolated on-
pump CABG, ticagrelor discontinuation >72 h and clopidogrel dis-
continuation >120 h before surgery were not associated with an
increased risk of bleeding-related complications [153].
Further evidence comes from a prospective, multicentre clin-
ical trial performed at 15 European centres, where discontinu-
ation of ticagrelor >2 days before surgery was not associated
with increased bleeding [160].
It is unlikely that the optimal discontinuation period for any
of the P2Y12 inhibitors will ever be tested in an RCT. As men-
tioned above, current guidelines recommend DAPT in all pa-
tients with ACS, independent of revascularization strategy [34,
161]. This applies to patients undergoing CABG and other car-
diac surgical procedures as well. Furthermore, the effect
of DAPT or single antiplatelet therapy after CABG has been
compared in two meta-analyses based on RCTs [148] or a com-
bination of RCTs and observational studies [149]. In the meta-
analysis based on RCTs only (which included 3717 ACS patients)
[148], there were no differences in all-cause mortality in ASA +
clopidogrel vs. ASA only. Conversely, all-cause mortality was
significantly lower in ASA + ticagrelor and ASA + prasugrel vs.
ASA + clopidogrel RCTs (RR 0.49, 95 % CI 0.33–0.71; P = 0.0002).
There were no significant differences in occurrence of MIs,
strokes, composite outcomes, or major bleeding (RR 1.31, 95 %
CI 0.81–2.10, P = 0.27). The meta-analysis based on both RCTs
and observational studies [149] included only DAPT patients
treated with clopidogrel. In this analysis, in-hospital or 30-day
Figure 5: Algorithm for dual antiplatelet therapy (DAPT) in patients with acute
coronary syndrome undergoing coronary artery bypass grafting. High bleeding
risk is considered as an increased risk of spontaneous bleeding during DAPT
(e.g. PRECISE-DAPT score >_25). Colour-coding refers to the ESC Classes of
Recommendations (green = Class I; yellow = IIa; orange = Class IIb). Treatments
presented within the same line are sorted in alphabetic order, no preferential
recommendation unless clearly stated otherwise.
1If patient is not eligible for a treatment with prasugrel or ticagrelor.
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mortality was lower with ASA + clopidogrel compared to ASA
alone (RR 0.38, 95% CI 0.26–0.57; P < 0.001), while the risk of
angina or perioperative MI was comparable (RR 0.60, 95% CI
0.31–1.14; P = 0.12). Long-term mortality was not reported.
Patients treated with ASA + clopidogrel demonstrated a trend to-
wards a higher incidence of major bleeding episodes as compared
to patients treated with ASA alone (RR 1.17, 95% CI 1.00–1.37; P =
0.05). In both meta-analyses, there was large heterogeneity between
the included studies regarding study drug (clopidogrel/prasugrel/
ticagrelor), study design, patient inclusion (ACS vs. stable CAD, on-
pump vs. off-pump surgery), study quality, and duration of follow-
up. The positive effect on survival appears to be more pronounced
in ACS patients and in patients treated with the second-generation
P2Y12 inhibitors ticagrelor and prasugrel. However, re-institution of
DAPT after CABG may also slightly increase the risk of bleeding
complications. Thus, it is recommended that DAPT is re-started as
soon as it is considered safe after CABG in ACS patients, with the ex-
ception of those on anticoagulation. There is currently no scientific
support for triple antithrombotic treatment after CABG. Resuming
DAPT early after CABG is most likely of special importance in pa-
tients with recent stent implantation, although strong evidence is
lacking. The optimal timing of resuming DAPT remains unclear, but
24–96 h after the operation in patients without recent stent implant-
ation appears reasonable. One reason for not starting DAPT imme-
diately after the operation is the considerable risk (30%) of atrial
fibrillation (AF) during the first postoperative days, which requires
oral anticoagulation [162].
Acetylsalicylic acid: A recent meta-analysis comparing pre-
operative ASA administration vs. no treatment or placebo in CABG
patients included 13 trials with a total of 2399 patients [163]. The
meta-analysis showed that treatment with ASA reduced the risk of
perioperative MI (OR 0.56, 95% CI 0.33–0.96) but not the mortality
risk (OR 1.16, 95% CI 0.42–3.22), while postoperative bleeding, red
blood cell transfusions, and surgical re-explorations increased with
ASA. The authors pointed out that included studies had low meth-
odological quality. The recent Aspirin and Tranexamic Acid for
Coronary Artery Surgery (ATACAS) trial compared administration
of ASA (100 mg) on the day of surgery vs. placebo in CABG pa-
tients [164]. The study showed no significant effect of ASA treat-
ment on perioperative bleeding. On the other hand, ASA
treatment did not reduce the incidence of thrombotic events. It
should be pointed out that the study did not directly compare dis-
continuation vs. no discontinuation, since the included patients
were only eligible for the trial if they were not using ASA preoper-
atively or had stopped ASA at least 4 days before surgery. Thus,
the ATACAS study does not directly apply to the ACS-CABG popu-
lation and does not change current recommendations of main-
taining ASA treatment during the perioperative period.
In a case-control study on 8641 CABG patients, those pre-
treated with ASA were less likely to experience in-hospital mor-
tality in univariate (OR 0.73, 95% CI 0.54–0.97) and multivariate
(OR 0.55, 95% CI 0.31–0.98) analysis relative to those not exposed
to ASA [165]. No significant difference was seen in the amount of
chest tube drainage, transfusion of blood products, or need for
re-exploration for bleeding, between patients who were or were
not exposed to ASA preoperatively.
Taken together, the evidence indicates that continuation of ASA
until cardiac surgery is associated with a moderately increased risk
Dual antiplatelet therapy in patients treated with cardiac surgery with stable or unstable coronary artery disease
Recommendations Classa Levelb
It is recommended that the heart team estimates the individual bleeding and ischaemic risks, and guides the timing of CABG
as well as the antithrombotic management.
I C
In patients on aspirin who need to undergo non-emergent cardiac surgery, it is recommended to continue aspirin at a low daily
regimen throughout the perioperative period.
I C
In patients treated with DAPT after coronary stent implantation who subsequently undergo cardiac surgery, it is recom-
mended to resume P2Y12 inhibitor therapy postoperatively as soon as is deemed safe so that DAPT continues until the recom-
mended duration of therapy is completed.
I C
In patients with ACS (NSTE-ACS or STEMI) treated with DAPT, undergoing CABG, and not requiring long-term OAC therapy, re-
sumption of P2Y12 inhibitor therapy as soon as is deemed safe after surgery and continuation up to 12 months is recommended.
I C
In patients on P2Y12 inhibitors who need to undergo non-emergent cardiac surgery, postponing surgery for at least 3 days
after discontinuation of ticagrelor, at least 5 days after clopidogrel, and at least 7 days after prasugrel should be considered
[152, 153, 160].
IIa B
In CABG patients with prior MI who are at high risk of severe bleeding (e.g. PRECISE-DAPT >_25), discontinuation of P2Y12 inhibitor
therapy after 6 months should be considered.
IIa C
Platelet function testing may be considered to guide decisions on timing of cardiac surgery in patients who have recently
received P2Y12 inhibitors [169, 172–174].
IIb B
In patients perceived to be at high ischaemic risk with prior MI and CABG, who have tolerated DAPT without a bleeding com-
plication, treatment with DAPT for longer than 12 and up to 36 months may be considered.
IIb C
ACS: acute coronary syndrome; CABG: coronary artery bypass graft surgery; DAPT: dual antiplatelet therapy; MI: myocardial infarction; NSTE-ACS: non-ST-
elevation acute coronary syndrome; OAC: oral anticoagulant; PRECISE-DAPT: PREdicting bleeding Complications In patients undergoing Stent implantation
and subsEquent Dual Anti Platelet Therapy; STEMI: ST-elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
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of bleeding complications and a significant reduction in the risk of
perioperative MI. If bleeding occurs during surgery, platelet transfu-
sion has been shown to effectively counteract ASA effects [166–168].
This finding further supports the possibility of continuing ASA
throughout the perisurgical period as ASA allows direct antiplatelet
effect reversal if clinically indicated. The increased risk of bleeding
complications if ASA and other antithrombotic drugs are not dis-
continued should be weighed against the potentially increased risk
of thrombotic complications during the preoperative cessation
period.
Platelet function testing: Besides the variance in platelet inhibi-
tory effects between different P2Y12 inhibitors, there is also a
large individual variation in the magnitude and duration of the
antiplatelet effect [20, 159, 169–171]. Because of the individual
variation, the use of platelet function tests may aid the optimiza-
tion of the timing of surgical procedures. However, platelet func-
tion tests could also be of value to establish the grade of platelet
inhibition in patients in whom the time since discontinuation is
unclear, e.g. in unconscious or confused patients, and in patients
with uncertain compliance to the treatment.
Treatment monitoring, using bedside tests, has been suggested
as an option for guiding interruption of treatment, rather than
the use of an arbitrary, specified period of time [156, 157]. Pre-
operative ADP-dependent platelet aggregation capacity predicts
CABG-related bleeding complications in clopidogrel- [172–174]
and ticagrelor-treated [169] ACS patients, and a strategy based
on preoperative platelet function testing, to determine the timing
of CABG in clopidogrel-treated patients, led to a 50% shorter
waiting time than that suggested by a simple discontinuation
time-based strategy [175]. It should be pointed out that the dif-
ferent platelet function tests and their respective cut-off levels are
not interchangeable [176]. Taken together, these results suggest
that platelet function testing in ACS patients referred for CABG is
of potential value to guide the timing of surgery in patients
treated with P2Y12 inhibitors. However, randomized studies with
clinically relevant endpoints are lacking.
5.3 Dual antiplatelet therapy for prevention of graft
occlusion
Two meta-analyses have compared graft patency in patients treated
with ASA alone or ASA + clopidogrel after CABG [149, 177]. The
studies included in the meta-analyses comprised mainly patients
with stable CAD. In a meta-analysis by Deo et al. [149], ASA + clopi-
dogrel was associated with a significant reduction in saphenous vein
graft occlusions (RR 0.59, 95% CI 0.43–0.82; P = 0.02). In the meta-
analysis by Nocerino et al. [177], DAPT was consistently associated
with a reduced occlusion rate (RR 0.63, 95% CI 0.46–0.86). DAPT
proved useful in preventing vein graft occlusion (RR 0.58, 95% CI
0.42–0.83), while no clear effect was shown in arterial grafts (RR
0.85, 95% CI 0.39–1.85) [177]. Weak evidence indicates that DAPT
may prevent graft occlusion in patients undergoing off-pump CABG
rather than on-pump CABG [178]. Given the low risk of thrombotic
events after CABG in stable patients, there is insufficient evidence to
generally recommend DAPT postoperatively to reduce vein graft oc-
clusion in this surgical patient subset.
5.4 Gaps in the evidence
There are several gaps in the evidence that pertain to the use
of DAPT in cardiac surgery. Clear gaps in evidence related to
DAPT in cardiac surgery patients include the question of whether
DAPT should be started after CABG in patients with stable
CAD. Also, the exact timing of postoperative DAPT restart re-
mains unclear, and it remains uncertain for how long the post-
operative DAPT should last. Further gaps in the evidence relate
to: the optimal time point for discontinuation of the different
P2Y12 inhibitors; the optimal use of platelet function testing in
patients awaiting cardiac surgery; how to manage perioperative
bleeding complications in cardiac surgery patients caused by
DAPT; and whether and how an incomplete response or inad-
equate antiplatelet effect of aspirin after CABG should be
addressed.
6. DUAL ANTIPLATELET THERAPY FOR PATIENTS
WITH MEDICALLY MANAGED ACUTE CORONARY
SYNDROME
The evidence for the use of DAPT in medically managed ACS
patients comes from the CHARISMA and CURE for clopidogrel
[40, 95], TRILOGY for prasugrel [24] and PLATO and PEGASUS
for ticagrelor studies [20, 29]. There is no evidence in favour of
prasugrel treatment in patients with ACS who are medically
managed, based on the negative results of the TRILOGY study
and the exclusion of this patient subset in the TRITON study
[23, 24]. The CURE study showed a consistent benefit in ACS pa-
tients undergoing an average mean of 9 months DAPT in the
form of aspirin and clopidogrel as compared to 1-month ther-
apy in NSTE-ACS patients, irrespective of the final management
strategy, including or not including coronary revascularization
[40]. The post-MI subset of patients in the CHARISMA trial
derived significant benefit with an NNT for benefit in the range
of 100, which came at the expense of higher major bleeding,
with an NNT for harm of 90 [135]. While the post-MI popula-
tion represents only a subset of those included in the
CHARISMA study and the overall results of the trial did not
show benefit of DAPT as compared to aspirin alone, it seems
justifiable to give credit to this subanalysis based on the consist-
ency of results within multiple recent studies; these studies
showed that the long-term administration of an intensified anti-
platelet regimen beyond 1 year of treatment reduced long-term
ischaemic recurrences, even if at the cost of higher bleeding
[29, 179].
Patients medically managed in the PLATO trial derived consist-
ent benefit from ticagrelor 90 mg b.i.d. as compared to clopidog-
rel. Overall mortality was also reduced in patients treated with
ticagrelor 90 mg b.i.d [180].
In the PEGASUS trial, 4271 patients had no prior coronary
stent implantation and they derived consistent benefits and risks
from ticagrelor vs. placebo on top of aspirin compared to pa-
tients with prior stenting.
Multiple sources have shown that medically managed ACS pa-
tients are less frequently treated with a DAPT regimen as
compared to patients who received PCI [181]. Current evidence,
especially for ticagrelor, does not support this practice and clin-
icians should refrain from tailoring the implementation and/or
duration of a DAPT regimen depending on prior coronary
stent implantation in the current era of newer-generation DES
(Figure 6).
A special population that warrants specific consideration
comprises patients with established NSTE-ACS in whom no
lumen obstruction at coronary angiography is detected. No
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dedicated study exists assessing the benefits and risks of DAPT
in this patient subset. However, a high prevalence of ruptured
plaques has been observed at intravascular imaging modalities
in this population [182], suggesting that the benefits of DAPT in
preventing recurrent MI should not be withheld from these pa-
tients if the risk of bleeding does not outweigh the anticipated
benefit.
The evidence in support of the DAPT treatment option in pa-
tients with STEMI conservatively managed or with prior lysis is
limited to 1 month of treatment [31, 32]. Yet, in consideration of
the fact that the majority of these patients would undergo inva-
sive management afterwards, and evidence that DAPT may be
beneficial irrespective of whether revascularization takes place, it
is reasonable to prolong DAPT further in these patients depend-
ing on the bleeding risk.
7. DUAL ANTIPLATELET THERAPY FOR PATIENTS
WITH INDICATION FOR ORAL
ANTICOAGULATION
7.1 Risk stratification and strategies to improve
outcome after percutaneous coronary intervention
Approximately 6–8% of patients undergoing PCI have an indication
for long-term oral anticoagulants (OACs) due to various conditions
such as AF, mechanical heart valves, or venous thromboembolism.
Compared with oral anticoagulation therapy alone, the addition of
DAPT to OAC therapy results in at least a two- to threefold increase
in bleeding complications [183–186]. Therefore, these patients
should be considered at high risk of bleeding, and the indication
for OAC should be reassessed and treatment continued only if a
compelling indication exists {e.g. paroxysmal, persistent, or
permanent AF with a CHA2DS2-VASc [Cardiac failure,
Hypertension, Age >_75 (2 points), Diabetes, Stroke (2 points)–
Vascular disease, Age 65–74, Sex category] score >_1 in men, >_2 in
women; mechanical heart valve; recent (i.e. 6 months) or a history
of recurrent deep venous thrombosis or pulmonary embolism}.
Conversely, every effort should be undertaken to implement strat-
egies to minimize PCI-related complications in these patients (Table
4). In particular, the duration of triple therapy should be limited or
omitted after hospital discharge (i.e. confined to the periprocedural
phase with aspirin being stopped thereafter), taking into account
the ischaemic (e.g. complexity of treated CAD, amount of disease
left untreated, technical considerations regarding stent implantation
techniques, and results) as well as the bleeding risks. While ischae-
mic risk scores also predict bleeding outcomes in AF [187], suggest-
ing considerable overlap among risk factors associated with
ischaemic and bleeding outcomes, multiple bleeding risk scores
[188], including the HAS-BLED [189] [Hypertension, Abnormal renal
and liver function (1 point each), Stroke, Bleeding history or predis-
position, Labile INR, Elderly (>65 years), Drugs and alcohol (1 point
each)] score, have been shown to outperform CHADS2 [Cardiac fail-
ure, Hypertension, Age, Diabetes, Stroke (Doubled)] or CHA2DS2-
VASc in predicting bleeding risk.
Importantly, HAS-BLED draws attention to the reversible bleeding
risk factors to be addressed by the responsible clinician during the
follow-up. Risk is not static and, particularly for bleeding, many
risk factors can be modified. Hence, a high risk of bleeding
(e.g. HAS-BLED score >_3) is not a reason to withhold OAC; instead,
such patients should be ‘flagged-up’ for more careful review and fol-
low-up.
More recently, the novel biomarker-based ABC [Age,
Biomarkers (GDF-15, cTnT-hs, and haemoglobin), and Clinical
history (previous bleeding)] [190] bleeding risk score has been
Dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing medical therapy management
Recommendations Classa Levelb
In patients with ACS who are managed with medical therapy alone and treated with DAPT, it is recommended to continue
P2Y12 inhibitor therapy (either ticagrelor or clopidogrel) for 12 months [20, 40].
I A
Ticagrelor is recommended over clopidogrel, unless the bleeding risk outweighs the potential ischaemic benefit [20]. I B
In patients with medically managed ACS who are at high risk of bleeding (e.g. PRECISE-DAPT >_25), DAPT for at least 1 month
should be considered.
IIa C
In patients with prior MI at high ischaemic riskc who are managed with medical therapy alone and have tolerated DAPT with-
out a bleeding complication, treatment with DAPT in the form of ticagrelor 60 mg b.i.d. on top of aspirin for longer than
12 months and up to 36 months may be considered [139].
IIb B
In patients with prior MI not treated with coronary stent implantation, who have tolerated DAPT without a bleeding complication and
who are not eligible for treatment with ticagrelor, continuation of clopidogrel on top of aspirin for longer than 12 months may be
considered.
IIb C
Prasugrel is not recommended in medically managed ACS patients [24]. III B
ACS: acute coronary syndrome; b.i.d.: bis in die; CrCl: creatinine clearance; DAPT: dual antiplatelet therapy; MI: myocardial infarction; PRECISE-DAPT:
PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy.
aClass of recommendation.
bLevel of evidence.
cDefined as >_ 50 years of age, and one or more of the following additional high-risk features: age of 65 years or older, diabetes mellitus requiring medication, a
second prior spontaneous myocardial infarction, multivessel coronary artery disease, or chronic renal dysfunction, defined as an estimated creatinine clear-
ance <60 ml/min.
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generated and validated in a broad AF population treated with
both vitamin K antagonist (VKA) and non-vitamin K oral anti-
coagulants (NOACs), and has shown superior prediction capabil-
ity as compared to HAS-BLED. However, similar to all other
bleeding risk scores, none of these risk prediction models de-
veloped for OAC patients has been prospectively tested in the
setting of prospective RCTs. Therefore, their value in improving
patient outcomes remains unclear.
A comprehensive list of all risk factors that have been associ-
ated with greater bleeding risk has been previously published
[162].
In the absence of safety and efficacy data from RCTs [only 6% of
patients were treated at baseline with ticagrelor or prasugrel in the
Rivaroxaban and a dose-adjusted oral VKA treatment strategy in
subjects with atrial fibrillation who undergo percutaneous coron-
ary intervention (PIONEER AF-PCI) study [191]] and worrisome
bleeding signals in registries, the use of prasugrel or ticagrelor as
part of triple therapy should be avoided [192]. Gastric protection
with a PPI is recommended. The dose intensity of OAC should be
carefully monitored with a target international normalized ratio
(INR) in the lower part of the recommended target range; in pa-
tients treated with NOACs, the lowest effective tested dose for
stroke prevention should be applied and criteria for drug accumu-
lation for each approved NOAC should be carefully assessed.
Lower NOAC regimens as compared to those tested in approval
studies are expected to decrease bleeding risk, but the trade-off
between bleeding and ischaemic (i.e. stroke prevention) outcomes
remains largely undefined. The PIONEER AF-PCI study [191]
(described in detail below) tested two lower rivaroxaban doses
(15 mg o.d. and 2.5 mg b.i.d.) as compared to the approved drug
regimen in AF patients (20 mg q.d.). The Evaluation of Dual
Therapy With Dabigatran vs. Triple Therapy With Warfarin in
Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI;
NCT02164864) will compare two dabigatran doses (150 mg b.i.d.
Table 4: Strategies to avoid bleeding complications in pa-
tients treated with oral anticoagulant
ABC: Age, Biomarkers, Clinical history; CHA2DS2-VASc: Congestive
heart failure, Hypertension, Age >_75 years (doubled), Diabetes mellitus,
prior Stroke or transient ischaemic attack or thromboembolism
(doubled), Vascular disease, Age 65–74 years, Sex category; HAS-BLED:
Hypertension, Abnormal renal/liver function, Stroke, Bleeding history
or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly;
NOAC: non-vitamin-K oral anticoagulant; INR: international normal-
ized ratio; PCI: percutaneous coronary intervention; PPIs: proton pump
inhibitors; VKA: vitamin K antagonist.
aApixaban 5 mg b.i.d or apixaban 2.5 mg b.i.d. if at least two of the fol-
lowing: age >_80 years, body weight <_60 kg or serum creatinine level
>_1.5 mg/dl (133 mmol/l); dabigatran 110 mg b.i.d.; edoxaban 60 mg q.d.
or edoxaban 30 mg q.d. if any of the following: creatinine clearance
(CrCl) of 30–50 ml/min, body weight <_60 kg, concomitant use of verap-
amil or quinidine or dronedarone; rivaroxaban 20 mg q.d. or rivaroxa-
ban 15 mg q.d. if CrCl 30–49 ml/min.
Figure 6: Algorithm for dual antiplatelet therapy (DAPT) in patients with acute
coronary syndrome undergoing medical management. High bleeding risk is con-
sidered as an increased risk of spontaneous bleeding during DAPT (e.g. PRECISE-
DAPT score >_25). Colour-coding refers to the ESC Classes of Recommendations
(green = Class I; yellow = IIa; orange = Class IIb). Treatments presented within the
same line are sorted in alphabetic order, no preferential recommendation unless
clearly stated otherwise.
1If patient is not eligible for a treatment with ticagrelor
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and 110 mg b.i.d.) vs. VKA and will provide additional insights with
respect to the balance between efficacy and safety for each one.
Whether there are differences according to the type of OAC
(NOACs vs. VKA) or stent platform as well the duration of triple
therapy is further discussed. These considerations do not pertain
to medically managed patients or to patients eligible for CABG sur-
gery in whom DAPT should be avoided on top of OAC.
7.2 Duration of triple therapy
Cessation of aspirin after PCI while maintaining clopidogrel has
been evaluated in the What is the Optimal antiplatElet and anti-
coagulant therapy in patients with OAC and coronary StenTing
(WOEST) trial, which randomized 573 patients (of whom 69% of
patients had AF) to dual therapy with OAC and clopidogrel
(75 mg/day) or to triple therapy with OAC, clopidogrel, and
aspirin 80 mg/day [193]. Treatment was continued for 1 month
after BMS placement and for 1 year after DES placement (65% of
patients). PCI was performed on VKA therapy in half of the pa-
tients. The primary endpoint of any TIMI bleeds assessed at 1-
year follow-up was significantly reduced in the dual-therapy arm
(19.5% vs. 44.9%; HR 0.36, 95% CI 0.26–0.50; P < 0.001), while no
significant difference in major bleeding was observed. The rates
of MI, stroke, target vessel revascularization, or stent thrombosis
did not differ significantly, but all-cause mortality was lower in
the dual-therapy group (2.5% vs. 6.4%; P = 0.027) at 1 year.
More recently, the PIONEER AF-PCI study randomized 2124
patients with non-valvular AF who had undergone PCI with
stenting to receive, in a 1:1:1 ratio: low-dose rivaroxaban (15 mg
o.d.) plus a P2Y12 inhibitor (and no ASA) for 12 months; very-low-
dose rivaroxaban (2.5 mg b.i.d.) plus DAPT for 1, 6, or 12 months;
or standard therapy with a dose-adjusted VKA plus DAPT for 1,
Figure 7: Algorithm for dual antiplatelet therapy (DAPT) in patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention (PCI).
Colour-coding refers to the number of concomitant antithrombotic medication(s). Triple therapy denotes treatment with DAPT plus oral anticoagulant (OAC). Dual
therapy denotes treatment with a single antiplatelet agent (aspirin or clopidogrel) plus OAC.
ABC: age, biomarkers, clinical history; ACS: acute coronary syndrome; mo.: month(s); PCI: percutaneous coronary intervention.
1Periprocedural administration of aspirin and clopidogrel during PCI is recommended irrespective of the treatment strategy.
2High ischaemic risk is considered as an acute clinical presentation or anatomical/procedural features which might increase the risk for myocardial
infarction.
3Bleeding risk can be estimated by HAS-BLED or ABC score.
60 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
Downloaded from https://academic.oup.com/ejcts/article-abstract/53/1/34/4095091
by Universitätsbibliothek Bern user
on 24 April 2018
6, or 12 months [191]. The primary safety endpoint, consisting of
TIMI clinically significant bleeding, was lower in the two groups
receiving rivaroxaban than in the group receiving standard ther-
apy [16.8% in patients treated with rivaroxaban 15 mg, 18% in pa-
tients treated with rivaroxaban 2.5 mg, and 26.7% in patients
treated with triple therapy (HR 0.59, 95% CI 0.47–0.76; P < 0.001,
and HR 0.63, 95% CI 0.50–0.80; P < 0.001, respectively)]. It is
worth mentioning that as many as 49% of patients in both DAPT
groups continued triple therapy for 12 months and no difference
in major bleeding or transfusion was observed across the groups.
Moreover, an INR range of 2–3 was recommended, instead of 2–
2.5, which may have inflated bleeding risk in the control group.
The rates of all-cause death, death from cardiovascular causes,
MI, or stroke were similar in the three groups [194]. However,
this study, similar to WOEST, was largely underpowered for the
assessment of meaningful differences in the incidence of relevant
ischaemic events such as stent thrombosis or stroke rates.
Therefore, uncertainty remains regarding the comparative per-
formance of three tested antithrombotic regimens in patients at
high stroke and/or stent thrombosis risk. Procedural characteris-
tics of coronary intervention have not been reported so far and
patients with prior stroke were excluded from participation. As a
result, the balance of ischaemic and bleeding risks of relatively
short (i.e. 6 months or less) triple therapy duration (possibly with
NOAC instead of VKA) as compared to double therapy consisting
of clopidogrel and OAC remains unknown and requires a
patient-by-patient decision.
Dual therapy with clopidogrel and OAC after PCI remains an
appealing alternative to triple therapy given that patients
exposed to OAC are at high bleeding risk, but more data, espe-
cially on efficacy and particularly in patients at high risk for stroke
and/or recurrent ACS, are needed. Cessation of clopidogrel while
maintaining aspirin has also been tested in the Triple Therapy in
Patients on Oral Anticoagulation After Drug Eluting Stent
Implantation (ISAR-TRIPLE) trial, where 614 patients (one-third
with ACS) undergoing stenting and requiring OAC were ran-
domly assigned to receive either 6-week or 6-month clopidogrel
therapy in addition to aspirin and VKA [195]. The primary end-
point of death, MI, stent thrombosis, ischaemic stroke, or TIMI
major bleeding at 9 months did not differ between the 6-week
and 6-month triple therapy (9.8% vs. 8.8%; HR 1.14, 95% CI 0.68–
1.91; P = 0.63); the same was true for the combined incidence of
death, MI, stent thrombosis, and ischaemic stroke (4.0% vs. 4.3%;
HR 0.93, 95% CI 0.43–2.05; P = 0.87). Furthermore, no difference
in TIMI major bleeding (5.3% vs. 4.0%; HR 1.35, 95% CI 0.64–2.84;
P = 0.44) was observed.
In all three studies, roughly one-third of patients presented with ACS.
There was no interaction between the duration of triple therapy and
clinical presentation (ACS vs. no ACS), which may reflect a real lack of
increased coronary ischaemic risk in these patients or a lack of power
to detect clinically meaningful differences in coronary ischaemic out-
comes if these patients undergo shorter duration of DAPT regimen (i.e.
1 month [195] or immediate discontinuation of aspirin after PCI [191,
193]). The rate of bleeding events peaked within the first 30 days of ini-
tiation of triple therapy and was twice as high when compared with
the rate of acute coronary events including recurrent MI and stent
thrombosis. These observations are consistent with the nationwide
Danish registry of AF all-comers with MI, where the 90-day bleeding
risk was increased on triple therapy compared with OAC plus a sin-
gle antiplatelet agent (HR 1.47, 95% CI 1.04–2.08), with a consistent
trend at 360 days (HR 1.36, 95% CI 0.95–1.95), without differences
in ischaemic events (HR 1.15, 95% CI 0.95–1.40) [196]. The same
registry suggests that warfarin plus clopidogrel resulted in a non-
significant reduction in major bleeds (HR 0.78, 95% CI 0.55–1.12)
compared with triple therapy, with a non-significant reduction in
MI or coronary death (HR 0.69, 95% CI 0.55–1.12) [197]. For these
reasons, duration of triple therapy should be minimized depending
on bleeding and ischaemic risks (Figure 7; Tables 5 and 6).
Dual antiplatelet therapy duration in patients with indi-
cation for oral anticoagulation
Recommendations Classa Levelb
It is recommended to administer periproce-
durally aspirin and clopidogrel in patients
undergoing coronary stent implantation.
I C
In patients treated with coronary stent implant-
ation, triple therapy with aspirin, clopidogrel, and
OAC should be considered for 1 month, irre-
spective of the type of stent used [195].
IIa B
Triple therapy with aspirin, clopidogrel, and
OAC for longer than 1 month and up to
6 months should be considered in patients
with high ischaemic risk due to ACS or other
anatomical/procedural characteristics that
outweigh the bleeding risk [195].
IIa B
Dual therapy with clopidogrel 75 mg/day and
OAC should be considered as an alternative to
1-month triple antithrombotic therapy in pa-
tients in whom the bleeding risk outweighs
the ischaemic risk [191, 193].
IIa A
Discontinuation of antiplatelet treatment in
patients treated with OAC should be con-
sidered at 12 months [198].
IIa B
In patients with an indication for VKA in combin-
ation with aspirin and/or clopidogrel, the dose in-
tensity of VKA should be carefully regulated with
a target INR in the lower part of the recom-
mended target range and a time in the thera-
peutic range >65–70% [193, 195].
IIa B
When a NOAC is used in combination with as-
pirin and/or clopidogrel, the lowest approved
dose effective for stroke prevention tested in AF
trials should be considered.c
IIa C
When rivaroxaban is used in combination
with aspirin and/or clopidogrel, rivaroxaban
15 mg q.d. may be used instead of rivaroxaban
20 mg q.d. [191].
IIb B
The use of ticagrelor or prasugrel is not rec-
ommended as part of triple antithrombotic
therapy with aspirin and OAC.
III C
ACS: acute coronary syndrome; AF: atrial fibrillation; b.i.d.: bis in die; CrCl: cre-
atinine clearance; INR: international normalized ratio; NOAC: non-vitamin K
oral anticoagulant; OAC: oral anticoagulant; q.d.: quaque die; VKA: vitamin K
antagonist.
aClass of recommendation.
bLevel of evidence.
cApixaban 5 mg b.i.d or apixaban 2.5 mg b.i.d. if at least two of the follow-
ing: age >_80 years, body weight <_60 kg or serum creatinine level >_1.5
mg/dl (133mmol/l); dabigatran 110 mg b.i.d.; edoxaban 60 mg q.d. or
edoxaban 30 mg q.d. if any of the following: CrCl of 30–50 ml/min, body
weight <_60 kg, concomitant use of verapamil, quinidine, or dronedarone;
rivaroxaban 20 mg q.d. or rivaroxaban 15 mg q.d. if CrCl 30–49 ml/min.
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7.3 Cessation of all antiplatelet agents
Data on the timing of cessation of any antiplatelet agents in
stented patients requiring chronic OAC are scarce. In stabilized
event-free patients, discontinuation of any antiplatelet agent at
1 year after stenting is encouraged in this patient population
based on studies demonstrating that OACs alone are superior to
aspirin post-ACS, and OAC + aspirin may not be more protective
but associated with excess bleeding [198]. Dual therapy with OAC
and one antiplatelet agent (aspirin or clopidogrel) may be con-
sidered beyond 1 year in patients at very high risk of coronary
events as defined in Table 5 [34] and in patients with mechanical
prosthesis and atherosclerotic disease.
7.4 Type of anticoagulants
PIONEER AF-PCI is the only randomized study comparing VKAs and
NOACs in patients with AF undergoing PCI for ACS or for stable
CAD (i.e. patients who have an indication to receive DAPT) [191].
However, in this study, two non-approved rivaroxaban regimens for
AF patients were tested and a low (i.e. 15 mg q.d.) or very low (i.e.
2.5 mg b.i.d.) rivaroxaban dose in combination with a single P2Y12 in-
hibitor or DAPT was compared to VKA plus DAPT, respectively. The
study was underpowered for ischaemic endpoints. Therefore, no
conclusion can be made on the advantages and limitations of each
OAC as compared to others. However, there was an excess of stroke
events in the 2.5 mg b.i.d. rivaroxaban arm in combination with 6-
month DAPT as compared to VKA and 6-month DAPT (6 vs. 0
events; P = 0.02).
In the four phase III NOAC AF trials, no interactions were dem-
onstrated between treatment effect and outcome according to
prior coronary status (ACS vs. no ACS), and it is likely that the
benefit of NOAC over VKA is preserved in CAD patients with AF
[199–202]. At least, this was the case among patients exposed to
antiplatelet therapy. There is no strong evidence for choosing
one NOAC over another. Dabigatran is the only NOAC that has
been tested in a phase III trial at reduced daily regimen (i.e.
110 mg b.i.d.) and for which non-inferiority vs. warfarin was
shown [199]. Although lower doses of other NOACs (i.e. apixaban
2.5 mg b.i.d. or edoxaban 30 mg o.d.) might be considered to re-
duce bleeding risk, these dosages have been evaluated only in a
subset of patients in the phase III trials based on prespecified
dosing algorithms. Their benefit in stroke prevention in patients
with a normal renal function is uncertain. Three ongoing large-
scale outcome studies are evaluating combinations of NOACs or
VKAs with antiplatelet therapy in AF patients undergoing stent-
PCI (NCT02164864, NCT02415400, and NCT02866175). Various
dose regimens of NOAC, different types of P2Y12 inhibitors, and
different exposure times are being evaluated.
7.5 Type of stent
The choice of newer-generation DES vs. BMS in patients requir-
ing long-term anticoagulation is no longer controversial. First,
data from the DAPT trial indicate a similar impact of prolonged
DAPT administration irrespective of stent type (BMS vs. DES)
[128], and the risk of adverse events among patients with DAPT
cessation and patients undergoing non-cardiac surgery indicate
no differences between BMS and DES [17, 129, 203]. Second, two
randomized trials have demonstrated the superiority of newer-
generation DES over BMS in high bleeding risk patients who can-
not tolerate long-term exposure to DAPT [130, 204], such as
those needing chronic OAC (section 2.2).
Altogether, both trials suggest that second-generation DES
should be the default choice in patients with high bleeding risk.
8. ELECTIVE NON-CARDIAC SURGERY IN
PATIENTS ON DUAL ANTIPLATELET THERAPY
It is estimated that 5–25% of patients with coronary stents may
require non-cardiac surgery within 5 years after stent implant-
ation [205]. Management of patients on DAPT who are referred
for surgical procedures involves consideration of: (1) the risk of
stent thrombosis (particularly if DAPT needs to be interrupted);
(2) the consequences of delaying the surgical procedure; and
(3) the increased intra- and periprocedural bleeding risk and
possible consequences of such bleeding if DAPT is continued
[206–208]. Given the complexity of these considerations,
Table 6: Unfavourable patient profile for a combination of
oral anticoagulant and antiplatelet therapy
Table 5: High-risk features of stent-driven recurrent ischae-
mic events
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a multidisciplinary approach—involving interventional cardiolo-
gists, cardiologists, anaesthetists, haematologists, and surgeons—is
required to determine the patient’s risk for bleeding and throm-
bosis and to choose the best management strategy. Surgical
interventions can be divided into low-risk, intermediate-risk, and
high-risk groups, with estimated 30-day cardiac event rates
for cardiac death or MI of <1%, 1–5%, and >_5%, respectively [205,
209]. A practical classification of the bleeding risk associated with
each type of non-cardiac surgery has been recently proposed by
the Stent After Surgery group [210].
In surgical procedures with low bleeding risk, every effort should
be taken not to discontinue DAPT perioperatively. In surgical pro-
cedures with moderate bleeding risk, patients should be maintained
on aspirin while P2Y12 inhibitor therapy should be discontinued
whenever possible. More challenging decision making is to be faced
among patients on DAPT who undergo high bleeding risk non-
cardiac surgeries, including vascular reconstructions, complex vis-
ceral procedures, neurosurgery, and transbronchial operations [211–
213]. In these cases, particular attention should be paid to timely dis-
continuation of P2Y12 inhibitor therapy to minimize the off-therapy
period before surgical intervention.
Discontinuation before non-cardiac surgery: To reduce the risk
of bleeding and transfusion, it is recommended to postpone
elective non-cardiac surgery until completion of the full course
of DAPT. In most clinical situations, aspirin provides benefit that
outweighs the bleeding risk and should be continued [214, 215].
Possible exceptions to this recommendation include intracranial
procedures, transurethral prostatectomy, intraocular procedures,
and operations with extremely high bleeding risk [157].
A higher risk of ischaemic events in the case of non-cardiac
surgery has been reported after first-generation DES [203] and a
higher risk for MACE has also been shown during the first weeks
after non-cardiac surgery in patients with implanted stents [203,
216, 217]. Furthermore, surgery per se, irrespective of the timing
of DAPT discontinuation, is associated with pro-inflammatory
and pro-thrombotic effects, thereby increasing the risk of coron-
ary thrombosis at the level of the stented vascular segment
as well as throughout the coronary vasculature [218, 219].
Therefore, in patients undergoing non-cardiac surgery after re-
cent ACS or stent implantation, the benefits of early surgery for a
specific pathology (e.g. malignant tumours or vascular aneurysm
repair) should be balanced against the risk of cardiovascular
events and the strategy should be discussed by a multidisciplin-
ary team.
Prior recommendations with regard to duration of DAPT [220,
221] and the timing of non-cardiac surgery [207, 222] in patients
treated with DES were based on observations of those treated
with first-generation DES. Compared with first-generation DES,
currently used newer-generation DES are associated with a lower
risk of stent thrombosis and appear to require a shorter min-
imum duration of DAPT [100, 103, 104, 223–225]. Furthermore,
in the PARIS registry, interruption of DAPT grounded on phys-
ician judgment in patients undergoing surgery at any time point
after PCI was not associated with an increased risk of MACE [17].
In the absence of a surgical control group, it remains challeng-
ing to identify a clear time frame after ACS or coronary stenting
where there is no additional risk or the risk is acceptably low for
patients to undergo surgery. Therefore, almost all registries have
attempted to identify such landmarks by looking at the time
course of the surgical ischaemic risk over time in order to identify
when it levels off and remains stable thereafter following an ACS
or stent implantation procedure [17]. By doing so, many registries
have reported that surgery-associated risk in DES-PCI-treated pa-
tients reaches a stable level after 3–6 months. [17, 214, 215]
However, without a surgical control group, these findings are po-
tentially influenced by the type and urgency of the surgical pro-
cedures. To overcome this limitation, two large matched cohorts
of patients undergoing surgery were recently reported. Using
Danish population-based registries and individual-based record
linkage of Danish registries, 4303 DES-PCI-treated patients who
underwent a surgical procedure within 12 months were identified
and were compared with a control group of patients without es-
tablished stable CAD undergoing similar surgical procedures (n =
20 232) [226]. This evaluation of the comparative risk associated
with surgery in DES-PCI-treated patients vs. patients without
known stable CAD revealed an increased overall risk for MI and
cardiac death in the patients with previous DES-PCI, owing to
higher MI rates but similar mortality risk [226]. However, this dif-
ference was highly time-dependent and limited to the first
month after DES-PCI [226]. These data suggest that surgery, if
possible, should be delayed for at least 1 month after DES-PCI.
Data for patients with coronary stents implanted in a Veterans’
Administration (VA) hospital from 2000 to 2010 were also re-
cently matched with VA Surgical Quality Improvement Program
data to identify non-cardiac surgery within 24 months of stent
placement [227]. Each patient with a stent(s) was matched with
two surgical patients without stents on surgical characteristics
and cardiac risk factors. The two groups had similar risk of ad-
verse cardiac events during 2 years of follow-up. However, pa-
tients with stents had a higher risk of adverse cardiac events
within the 30-day postoperative period [227]. The incremental
risk did not vary by stent type [227]. In both studies, roughly 50%
of patients underwent stenting because of ACS and no incremen-
tal risk was observed in this higher risk population as compared
to stable CAD patients.
Therefore, a minimum of 1 month of DAPT should be con-
sidered, independently of the type of implanted stent (i.e. BMS
or newer-generation DES), in cases when surgery cannot be
delayed for a longer period; however, such surgical procedures
should be performed in hospitals where catheterization laborato-
ries are available 24/7, so as to treat patients immediately in case
of perioperative thrombotic events (Figure 8). In patients at high
ischaemic risk due to ACS presentation or complex coronary
revascularization procedure, delaying surgery up to 6 months
after index ACS or PCI may be reasonable as an additional safe-
guard to minimize the risk of perisurgical MI, and based on un-
matched retrospective registry data if the risks of further delaying
surgery are acceptable.
In patients needing surgery within a few days, it was previously
recommended to withhold clopidogrel and ticagrelor for 5 days
and prasugrel for 7 days prior to surgery unless there is a high
risk of thrombosis [228]. However, emerging evidence, which is
extensively discussed in Chapter 5, challenges such a long discon-
tinuation period for ticagrelor before a safe surgical procedure
can be undertaken (Figure 9) [152, 153].
Although these data refer to patients undergoing cardiac sur-
gery, it is rational to extend these findings to the non-cardiac sur-
gery population, given the same offset kinetics and principally
lower risk of bleeding in non-cardiac surgeries relative to cardiac
surgery procedures (Figure 9). In cases where the consequences
of even minor bleeding would be unacceptable (e.g. spinal sur-
gery or other neurosurgical procedures) or the bleeding risk
largely outweighs the ischaemic risk (e.g. a medium- to high-risk
surgical bleeding procedure is undertaken 6 months or more
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after single stent implantation for stable CAD indication), P2Y12
inhibitors may be discontinued for a longer duration of time to
ensure no residual platelet inhibition at the time of planned sur-
gery. For patients with a very high risk of stent thrombosis, bridg-
ing therapy with intravenous, reversible glycoprotein inhibitors,
such as eptifibatide or tirofiban [229], may be considered.
Cangrelor, a reversible intravenous P2Y12 inhibitor, has been
shown to provide effective platelet inhibition [230] and is an ap-
pealing alternative to glycoprotein IIb/IIIa inhibitors [231], given
the well-known role of P2Y12 inhibition in preventing stent
thrombosis and the quicker offset of action as compared to tiro-
fiban or eptifibatide. Concomitant parenteral anticoagulation
therapy in conjunction with cangrelor or reversible glycoprotein
inhibitors is not recommended to minimize bleeding risk while
awaiting surgical procedures.
Restart after surgery: If P2Y12 inhibitor therapy has been
stopped before a surgical procedure, therapy should be re-
started as soon as possible (within 48 h), given the substantial
thrombotic hazard associated with lack of platelet inhibition
early after surgery in patients with recent stent implantation
and/or an ACS episode (Figure 9) [232, 233].
The time for restarting P2Y12 inhibitors after surgery should ul-
timately be determined via a multidisciplinary discussion before
surgery and traced in the patient file.
9. GENDER CONSIDERATION AND SPECIAL
POPULATIONS
9.1 Gender specificities
There is no convincing evidence for a gender-related difference in the
efficacy and safety of currently available DAPT type or duration across
studies. No single trial or pooled analysis of investigations assessing a
shorter than 1 year vs. at least 1 year DAPT duration has shown het-
erogeneous findings across genders [26, 112, 240, 241]. In the DAPT
trial, there was a borderline quantitative interaction suggesting a lower
relative treatment benefit for stent thrombosis reduction with
Figure 8: Timing for elective non-cardiac surgery in patients treated with dual
antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI).
Colour-coding refers to the ESC Classes of Recommendations (green = Class I;
yellow = IIa; orange = Class IIb).
ACS: acute coronary syndromes.
1Availability of H24 cath-lab service in place is suggested in case of major
surgery within 6 months after PCI.
2High ischaemic risk features are presented in Table 5.
Dual antiplatelet therapy in patients undergoing elective
non-cardiac surgery
Recommendations Classa Levelb
It is recommended to continue aspirin perio-
peratively if the bleeding risk allows, and to
resume the recommended antiplatelet ther-
apy as soon as possible postoperatively
[232–236].
I B
After coronary stent implantation, elective
surgery requiring discontinuation of the P2Y12
inhibitor should be considered after 1 month,
irrespective of the stent type, if aspirin can be
maintained throughout the perioperative
period [227].
IIa B
Discontinuation of P2Y12 inhibitors should be
considered at least 3 days before surgery for
ticagrelor, at least 5 days for clopidogrel, and
at least 7 days for prasugrel [152, 153, 160].
IIa B
A multidisciplinary expert team should be
considered for preoperative evaluation of pa-
tients with an indication for DAPT before
elective surgery.
IIa C
In patients with recent MI or other high is-
chaemic risk featuresc requiring DAPT, elect-
ive surgery may be postponed for up to
6 months [17, 214, 215, 234].
IIb C
If both oral antiplatelet agents have to be dis-
continued perioperatively, a bridging strategy
with intravenous antiplatelet agents may be
considered, especially if surgery has to be per-
formed within 1 month after stent implant-
ation [229, 237–239].
IIb C
It is not recommended to discontinue DAPT
within the first month of treatment in pa-
tients undergoing elective non-cardiac
surgery [203].
III B
DAPT: dual antiplatelet therapy; MI: myocardial infarction.
aClass of recommendation.
bLevel of evidence.
cHigh ischaemic risk features are provided in Table 5.
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prolonged DAPT in female as compared to male patients (Pint =0.04)
[26]. However, no such signal was apparent for MACCE (Pint = 0.46) or
bleeding (Pint = 0.40) endpoints. Within the PEGASUS trial, there was
no signal suggesting heterogeneity across the primary study endpoint
with respect to gender (Pint = 0.84) [29]. On the other hand, there was
a positive quantitative interaction (Pint = 0.03) suggesting that female
patients may derive a relatively greater treatment benefit with respect
to stroke prevention from prolonged treatment with aspirin and tica-
grelor as compared to aspirin alone. However, no such signal was evi-
dent for cardiovascular death, MI, or safety endpoints.
9.2 Diabetes mellitus
Patients with diabetes mellitus presenting with both stable and un-
stable CAD carry a worse prognosis in terms of short- and long-
term risks of fatal and non-fatal ischaemic events, with enhanced
platelet hyperactivity playing a putative causal role. In the CURE trial,
patients with diabetes derived a similar treatment benefit from the
addition of clopidogrel on top of aspirin as compared to patients
without [40]. No signal for greater treatment benefit was apparent in
TRITON-TIMI 38 in patients with diabetes as compared to those
without with respect to the study primary endpoint, and a consistent
lack of heterogeneity signal with respect to diabetes mellitus was
observed in the PLATO trial [20, 23]. Hence, there is no convincing
evidence that the presence of diabetes should affect decision mak-
ing with respect to the choice of P2Y12 inhibitors.
As it related to DAPT duration, the DAPT study found a slightly
lower relative risk reduction for MI endpoint in patients with dia-
betes as compared to those without diabetes (Pint = 0.02) [242].
However, there was no signal for heterogeneity with respect to the
concomitant presence of diabetes mellitus across all other ischae-
mic or safety endpoints. Finally, no difference with respect to the
presence or absence of diabetes was observed for the primary effi-
cacy endpoint in the PEGASUS study (Pint = 0.99) [145]. Altogether,
current evidence suggests that diabetes mellitus should not be the
only appraised patient-specific feature when deciding upon the
type or duration of DAPT.
9.3 Lower-extremities artery disease
Patients with LEAD are at heightened risk of ischaemic complica-
tions and mortality. The combination of symptomatic LEAD and
CAD is associated with further heightened ischaemic risk beyond
that associated with symptomatic disease in either vascular bed
alone [243]. In 3096 patients with LEAD included in the CHARISMA
trial, DAPT was associated with a lower rate of MI and hospitaliza-
tion for ischaemic events but not the overall composite primary
endpoint. There was no difference between the groups in moderate,
severe, or fatal bleeding, but there was an increase in minor bleed-
ing in the DAPT group [244]. The PEGASUS investigators recently
examined a subgroup of 1143 patients with LEAD and found that
patients with prior MI with LEAD had a 60% increased risk of MACE
relative to patients without LEAD, even after adjusting for differences
in baseline characteristics [140]. This increased ischaemic risk trans-
lated into a robust absolute risk reduction of 5.2% at 3 years with
ticagrelor 60 mg b.i.d. compared with placebo. In the setting of this
robust ischaemic risk reduction, there were significant reductions in
cardiovascular and all-cause mortality. Treatment with ticagrelor vs.
placebo reduced the risk of adverse limb events in addition to the
benefits observed for MACE and mortality. Reductions in acute limb
ischaemia have also been shown with other antiplatelet agents, such
as vorapaxar, demonstrating that this morbidity is modifiable with
potent and prolonged antithrombotic strategies [245]. In the all-
comer PRODIGY trial, 246 (12.5%) patients were included with
symptomatic LEAD. LEAD status was associated with a higher risk of
death and ischaemic events (HR 2.80, 95% CI 2.05–3.83; P < 0.001)
[246]. Prolonged vs. short DAPT conveyed a lower risk of the pri-
mary efficacy endpoint in LEAD patients (16.1% vs. 27.3%; HR 0.54,
95% CI 0.31–0.95; P = 0.03) but not in patients without LEAD (9.3%
vs. 7.4%; HR 1.28, 95% CI 0.92–1.77; P = 0.14), with positive inter-
action (P = 0.01). The risk of definite or probable stent thrombosis
as well as overall mortality was significantly lower in LEAD patients
treated with prolonged DAPT as compared with those receiving
short DAPT.
9.4 Complex percutaneous coronary intervention
While high PCI complexity intuitively represents a driver for fa-
vouring a prolonged over a shortened DAPT duration, the evi-
dence regarding optimal DAPT duration based on complexity of
intervention is limited. In a patient-level meta-analysis from six
RCTs investigating DAPT durations after coronary stenting,
including 9577 patients, complex PCI was defined as the com-
posite of at least three stents implanted, at least three lesions
Figure 9: Minimal discontinuation and re-implementation time frames of dual antiplatelet therapy (DAPT) for patients undergoing elective surgery
OAC: oral anticoagulant.
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Figure 10: Practical recommendations for the management of bleeding in patients treated with dual antiplatelet therapy with or without concomitant oral anticoagu-
lation. Practical recommendations for the management of bleeding in patients treated with dual antiplatelet therapy with or without concomitant oral anticoagula-
tion. Blue boxes refer to management of antiplatelet therapy. Dark-red boxes refer to the management of oral anticoagulation. Light-green boxes refer to general
recommendation for patients’ safety.
ACS: acute coronary syndrome; CHA2DS2-VASc: cardiac failure, hypertension, age >_75 (2 points), diabetes, stroke (2 points)–vascular disease, age 65–74, sex category;
DAPT: dual antiplatelet therapy; GI: gastrointestinal; HB: haemoglobin; INR: international normalized ratio; i.v.: intravenous; OAC: oral anticoagulant; NOAC: non-vita-
min-K antagonist; PPI: proton pump inhibitor; RBC: red blood cell; SAPT: single antiplatelet therapy.
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treated, bifurcation with two stents implanted, total stent length
>60 mm, and chronic total occlusion as target lesion [247].
Patients who underwent complex PCI had a two-fold increase of
MACE (5.0% vs. 2.5%; P = 0.001). Long- and short-DAPT were
defined as a DAPT duration >_12 months and <_6 months, respect-
ively. Compared with short-DAPT, long-DAPT was associated
with a significant reduction in MACE in the complex PCI group
(4.0% vs. 6.0%; adjusted HR 0.56, 95% CI 0.35–0.89) vs. the non-
complex PCI group (2.5% vs. 2.6%; adjusted HR 1.01, 95% CI
0.75–1.35; Pint = 0.01). The magnitude of the reduction in MACE
with long-DAPT increased progressively as the degree of proced-
ural complexity was greater. Long-DAPT was overall associated
with increased risk of major bleeding, which was uniform in mag-
nitude between groups (Pint = 0.15).
Figure 10: Continued
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9.5 Dual antiplatelet therapy decision making in
patients with stent thrombosis
Patients presenting with stent thrombosis represent a challenging
patient population in whom no randomized clinical evidence is
available to guide decision making. Observational studies have
shown that the risk of stent thrombosis recurrence after the first
episode of stent thrombosis is worrisome. Armstrong et al. re-
ported on a combined retrospective and prospective observational
California registry of angiographic definite stent thrombosis at five
academic hospitals from 2005 to 2013 [248]. The entry criterion
was the occurrence of a definite stent thrombosis, which was
observed in 221 patients overall out of an unknown number of pa-
tients at risk. With the important caveat of not knowing for each
stent type the exact timing of the first stent thrombosis event after
the index procedure, 104 (47%) patients had received a first gener-
ation DES, 51 (23%) a BMS, and 19 (9%) a second generation DES.
After a median follow-up of 3.3 years, 29 patients developed defin-
ite or probable recurrent stent thrombosis, while 19 presented
angiographic definite recurrent stent thrombosis. The cumulative
hazard of definite or probable recurrent stent thrombosis was 16%
at 1 year and 24% at 5 years. The cumulative hazard of angio-
graphic definite recurrent stent thrombosis was 11% at 1 year and
20% at 5 years. Taken together, these findings confirm the high risk
of stent thrombosis recurrence after the first stent thrombosis. An
additional piece of information, which is conveyed by this import-
ant analysis, is that the risk of recurrence is highest in the first few
months after the first event and that it does not abate entirely
over time. Both prasugrel and ticagrelor have been shown to be
associated with a significant reduction of definite and definite or
probable stent thrombosis as compared to clopidogrel [20, 23].
Moreover, both studies indicated that the number of recurrent
events is also significantly decreased by treatment with ticagrelor
or prasugrel as compared to clopidogrel. Hence, the use of clopi-
dogrel after stent thrombosis cannot be regarded as an effective
treatment option. Considering the long-term risk of recurrence
after first stent thrombosis, it may be reasonable to make every ef-
fort to maintain DAPT for a very long-term period in this highly
selected high-risk patient population, if tolerated.
9.6 Patients who develop bleeding while on
treatment
Patients who develop bleeding complications while on DAPT
represent a challenging patient population for whom no guid-
ance from RCTs is available.
The decision to withhold or continue DAPT in this setting
largely depends on ischaemic (e.g. indication for DAPT and time
from last stent insertion, if any, to bleeding) vs. recurrent/pro-
longed bleeding risks. A practical flow chart in order to manage
this challenging population is provided in Figure 10 and add-
itional information on practical management can be found else-
where [249]. As bleeding is an independent predictor of recurrent
bleeding [250], type, dose, and duration of DAPT should be re-
assessed in this setting.
10. KEY MESSAGES
1. Benefits and risks of DAPT: DAPT reduces the risk of stent throm-
bosis across the entire spectrum of events, from acute to very late
occurrences. However, treatment with DAPT beyond 1 year after
MI, or after PCI, exerts the majority of its benefit by reducing the
rate of spontaneous MI. The risk of bleeding in patients on DAPT is
proportionally related to its duration both within and beyond
1 year of treatment duration. Since the benefits of prolonged DAPT,
especially for mortality endpoints, appear highly dependent on
prior cardiovascular history (such as prior ACS/MI vs. stable CAD),
and prediction models to estimate on-DAPT bleeding risk have
been developed, an individualized approach based on ischaemic
vs. bleeding risk assessment is warranted.
2. Bleeding mitigation strategy: Every effort should be pursued to miti-
gate the risk of bleeding complications while the patent is on
DAPT, including access site selection, modulation of modifiable risk
factors for bleeding, low dose aspirin, low dose of P2Y12 inhibitor
as appropriate, and routine use of PPI.
Gender considerations and special populations
Recommendations Classa Levelb
Similar type and duration of DAPT are recom-
mended in male and female patients [26, 240].
I A
It is recommended to reassess the type, dose,
and duration of DAPT in patients with action-
able bleeding complications while on
treatment.
I C
Similar type and duration of DAPT should be
considered in patients with and without dia-
betes mellitus [145, 242].
IIa B
Prolonged (i.e. >12 monthsc) DAPT duration
should be considered in patients with prior
stent thrombosis, especially in the absence of
correctable causes (e.g. lack of adherence or
correctable mechanical stent-related issues).
IIa C
Prolonged (i.e. >12 months) DAPT duration
may be considered in CAD patients with LEAD
[140, 246].
IIb B
Prolonged (i.e. >6 months) DAPT durationd
may be considered in patients who under-
went complex PCI [247].
IIb B
CAD: coronary artery disease; DAPT: dual antiplatelet therapy; LEAD:
lower-extremities artery disease; PCI: percutaneous coronary
intervention.
aClass of recommendation.
bLevel of evidence.
cPossibly for as long as can be tolerated.
dComplex PCI defined as the composite of at least three stents im-
planted, at least three lesions treated, bifurcation with two stents im-
planted, total stent length >60 mm, and chronic total occlusion as
target lesion.
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3. P2Y12 inhibitor selection: Clopidogrel is considered the default
P2Y12 inhibitor in patients with stable CAD treated with PCI, those
with indication to concomitant oral anticoagulation, as well as in
ACS patients in whom ticagrelor or prasugrel are contraindicated.
Ticagrelor or prasugrel is recommended in ACS patients unless
drug-specific contraindications exist.
4. Timing of P2Y12 inhibitor initiation: The timing of initiation of a
P2Y12 inhibitor is both drug- (i.e. ticagrelor or clopidogrel vs. prasu-
grel) and disease-specific (i.e. SCAD vs. ACS and type thereof).
5. Stable CAD patients treated with PCI: Irrespective of the type of me-
tallic stent implanted, the duration of DAPT is 1–6 month(s) depend-
ing on the bleeding risk. For patients in whom the ischaemic risk
prevails over the risk of bleeding, a longer DAPT duration may be
considered.
6. Metallic stent type and DAPT duration: The need for a short DAPT
regimen should no longer justify the use of BMS instead of newer-
generation DES. DAPT duration in each individual patient should
be guided by an individualized approach based on ischaemic vs.
bleeding risk assessment and not by the stent type.
7. Stable CAD patients treated with CABG: There is insufficient data to
recommend DAPT in this patient population.
8. ACS patients: Irrespective of the final revascularization strategy (e.g.
medical therapy, PCI, or CABG), the default DAPT duration in these
patients is 12 months. Six-month therapy duration should be con-
sidered in high bleeding risk patients, whereas >12-month therapy
may be considered in ACS patients who have tolerated DAPT with-
out a bleeding complication.
9. Patients with indication for oral anticoagulation: Compared with
OAC therapy alone, the addition of DAPT to OAC therapy results
in at least a two- to three-fold increase in bleeding complications.
Therefore, these patients should be considered at high risk of
bleeding and the indication for OAC should be reassessed and
treatment continued only if a compelling indication exists.
The duration of triple therapy should be limited up to a maximum
of 6 months or omitted after hospital discharge, taking into account
the ischaemic (e.g. complexity of treated CAD, amount of disease
left untreated, technical considerations regarding stent implant-
ation techniques, and results) as well as the bleeding risk. The use
of ticagrelor or prasugrel in this setting is not recommended.
10. Patients undergoing elective non-cardiac surgery after coronary stent
implantation: A multidisciplinary expert team should be considered
for preoperative evaluation of patients with an indication for DAPT
before elective surgery. Scheduled surgery requiring discontinuation
of the P2Y12 inhibitor should be considered after at least 1 month, ir-
respective of the stent type, if aspirin can be maintained throughout
the perioperative period. If both oral antiplatelet agents have to be
discontinued perioperatively, a bridging strategy with cangrelor, tiro-
fiban, or eptifibatide may be considered, especially if surgery has to
be performed within 1 month after stent implantation.
11. Gender consideration and special populations: Similar type and
duration of DAPT are recommended in male and female patients,
as well as in patients with and without diabetes mellitus. Patients
with prior stent thrombosis, especially in the absence of correctable
causes, should receive prolonged DAPT. A prolonged DAPT regi-
men may also be considered in patients with LEAD or who have
undergone complex PCI. It is recommended to reassess the type,
dose, and duration of DAPT in patients with actionable bleeding
complications while on treatment. In patients with active bleeding
while on DAPT, the decision to stop both antiplatelet agents, espe-
cially if shortly after PCI, should be taken only if the bleeding is life-
threatening and the source has not been or cannot be treated. In
such a rare case scenario, the patient should be transferred to a pri-
mary PCI facility centre.
11. EVIDENCED-BASED ‘TO DO AND NOT TO DO’
MESSAGES
Recommendations that are class I or III with a level of evidence A or B
Recommendations on P2Y12 inhibitor selection and timing Class
a Levelb
In patients with ACS, ticagrelor (180 mg loading dose, 90 mg b.i.d.) on top of aspirin is recommended, regardless of initial treatment
strategy, including patients pre-treated with clopidogrel (which should be discontinued when ticagrelor is commenced) unless
there are contraindications.c
I B
In patients with ACS undergoing PCI, prasugrel (60 mg loading dose, 10 mg o.d.) on top of aspirin is recommended for P2Y12 inhibitor-naı̈ve
patients with NSTE-ACS or initially conservatively managed STEMI if indication for PCI is established, or in STEMI patients undergoing imme-
diate coronary catheterization unless there is a high risk of life-threatening bleeding or other contraindications.c
I B
Pre-treatment with a P2Y12 inhibitor is generally recommended in patients in whom coronary anatomy is known and the decision
to proceed to PCI is made, as well as in patients with STEMI.
I A
Clopidogrel (600 mg loading dose, 75 mg o.d.) on top of aspirin is recommended in stable CAD patients undergoing
coronary stent implantation and in ACS patients who cannot receive ticagrelor or prasugrel, including those with prior intracranial
bleeding or indication for OAC.
I A
Clopidogrel (300 mg loading dose in patients aged <_75, 75 mg o.d.) is recommended on top of aspirin in STEMI patients receiving
thrombolysis.
I A
In NSTE-ACS patients in whom coronary anatomy is not known, it is not recommended to administer prasugrel. III B
Measures to minimize bleeding while on dual antiplatelet therapy
Radial over femoral access is recommended for coronary angiography and PCI if performed by an expert radial operator. I A
In patients treated with DAPT, a daily aspirin dose of 75–100 mg is recommended. I A
A PPI in combination with DAPT is recommended.d I B
Continued
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Routine platelet function testing to adjust antiplatelet therapy before or after elective stenting is not recommended. III A
Switching between oral P2Y12 inhibitors
In patients with ACS who were previously exposed to clopidogrel, switching from clopidogrel to ticagrelor is recommended early
after hospital admission at a loading dose of 180 mg irrespective of timing and loading dose of clopidogrel, unless contraindications
to ticagrelor exist.c
I B
Dual antiplatelet therapy duration in patients with acute coronary syndrome treated with percutaneous coronary intervention
In patients with ACS treated with coronary stent implantation, DAPT with a P2Y12 inhibitor on top of aspirin is recommended for
12 months unless there are contraindications such as excessive risk of bleeding (e.g. PRECISE-DAPT >_25).
I A
Dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing medical therapy management
In patients with ACS who are managed with medical therapy alone and treated with DAPT, it is recommended to continue P2Y12 in-
hibitor therapy (either ticagrelor or clopidogrel) for 12 months.
I A
Ticagrelor is recommended over clopidogrel, unless the bleeding risk outweighs the potential ischaemic benefit. I B
Prasugrel is not recommended in medically managed ACS patients. III B
Dual antiplatelet therapy in patients undergoing elective cardiac and non-cardiac surgery
It is recommended to continue aspirin perioperatively if the bleeding risk allows, and to resume the recommended antiplatelet ther-
apy as soon as possible postoperatively.
I B
It is not recommended to discontinue DAPT within the first month of treatment in patients undergoing elective non-cardiac surgery. III B
Gender considerations
Similar type and duration of DAPT are recommended in male and female patients. I A
ACS: acute coronary syndrome; CAD: coronary artery disease; DAPT: dual antiplatelet therapy; NSTE-ACS: non-ST elevation acute coronary syndrome; OAC: oral anti-
coagulant; o.d.: omni die (once a day); PCI: percutaneous coronary intervention; PPI: proton pump inhibitor; PRECISE-DAPT: PREdicting bleeding Complications In pa-
tients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy; STEMI: ST-elevation myocardial infarction; TIA: transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
cContraindications for ticagrelor: previous intracranial haemorrhage or ongoing bleeds. Contraindications for prasugrel: previous intracranial haemorrhage,
previous ischaemic stroke or TIA, or ongoing bleeds; prasugrel is not recommended for patients >_75 years of age or with a body weight <60 kg.
dWhile the evidence that a PPI does not increase the risk of cardiovascular events was generated with omeprazole, based on drug–drug interaction studies, ome-
prazole and esomeprazole would appear to have the highest propensity for clinically relevant interactions, while pantoprazole and rabeprazole have the lowest.
What is new in the 2017 ESC focussed update on DAPT?
New/revised concepts
Metallic stent and DAPT duraon
Switch between P2Y12 inhibitors
Risk scores to guide DAPT duraon
−PRECISE DAPT score
−DAPT score
Specific profiling
−Definion of complex PCI
−Unfavourable profile for OAC and APT
−Gender consideraons and 
special populaons
DAPT duraon without stenng
−Medical management
−CABG or cardiac surgery
Ancoagulaon and DAPT
−Acute and chronic seng
−Dosing regimen
Pretreatment with P2Y12 inhibitors 
when PCI is planned
Liberal use of PPI to migate GI bleeding 
risk
Ticagrelor interrupon of 3 days prior 
elecve surgery
Roune platelet funcon tesng to adjust 
therapy
Dual therapy as an alternave to triple 
therapy when bleeding risk outweighs the 
ischaemic risk 
Change in recommendaons
Disconnuaon of P2Y12 inhibitor therapy 
aer 6 months when stenng ACS paents 
with PRECISE-DAPT ≥ 25
New recommendaons 2017
I
7102erofeB
Disconnuaon of anplatelet treatment 
in paents treated with OAC should be 
considered at 12 months. 
The occurrence of aconable bleeding while 
on DAPT should prompt reconsideraon of 
type and duraon of DAPT regimen. 
The decision for DAPT duraon should be 
dynamic and reassessed during the course 
of the inially selected DAPT regimen. 
IIB
6-month DAPT regimen In paents with 
SCAD treated with drug-coated balloon 
Ticagrelor 60 mg b.i.d preferred over other 
oral P2Y12 inhibitors for DAPT connuaon 
>12 months in post-MI 
IIIIIA
Early administraon of cagrelor/ clopidogrel 
in NSTE-ACS with invasive approach
Elecve surgery requiring disconnuaon 
of the P2Y12 inhibitor aer 1 month
ACS: acute coronary syndrome; APT: anti-platelet therapy; CABG: coronary artery bypass graft; DAPT: dual antiplatelet therapy; MI: myocardial infarction; NSTE: non-ST-
segment elevation; OAC: oral anti-coagulant;PCI: percuatenous coronary intervention; PRECISE-DAPT: PREdicting bleeding Complications In patients undergoing Stent
implantation and subsEquent Dual Anti Platelet Therapy; Stable CAD: stable coronary artery disease.
70 ESC Guidelines / European Journal of Cardio-Thoracic Surgery
Downloaded from https://academic.oup.com/ejcts/article-abstract/53/1/34/4095091
by Universitätsbibliothek Bern user
on 24 April 2018
12. WEB ADDENDA AND CLINICAL CASES
COMPANION DOCUMENT
All Web figures, Web tables, and the Clinical Cases companion
document are available at the European Heart Journal online and
also via the ESC Web site at: www.escardio.org/guidelines
13. APPENDIX
ESC Committee for Practice Guidelines (CPG): Stephan
Windecker (Chairperson) (Switzerland), Victor Aboyans (France),
Stefan Agewall (Norway), Emanuele Barbato (Italy), Héctor Bueno
(Spain), Antonio Coca (Spain), Jean-Philippe Collet (France), Ioan
Mircea Coman (Romania), Veronica Dean (France), Victoria
Delgado (The Netherlands), Donna Fitzsimons (UK), Oliver
Gaemperli (Switzerland), Gerhard Hindricks (Germany), Bernard
Iung (France), Peter Jüni (Canada), Hugo A. Katus (Germany),
Juhani Knuuti (Finland), Patrizio Lancellotti (Belgium), Christophe
Leclercq (France), Theresa McDonagh (UK), Massimo Francesco
Piepoli (Italy), Piotr Ponikowski (Poland), Dimitrios J. Richter
(Greece), Marco Roffi (Switzerland), Evgeny Shlyakhto (Russia),
Iain A. Simpson (UK), and Jose Luis Zamorano (Spain)
ESC National Cardiac Societies actively involved in the re-
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ation with EACTS:
Austria: Austrian Society of Cardiology, Franz Xaver Roithinger;
Azerbaijan: Azerbaijan Society of Cardiology, Farid Aliyev;
Belarus: Belorussian Scientific Society of Cardiologists, Valeriy
Stelmashok; Belgium: Belgian Society of Cardiology, Walter
Desmet; Bulgaria: Bulgarian Society of Cardiology, Arman
Postadzhiyan; Cyprus: Cyprus Society of Cardiology, Georgios P.
Georghiou; Czech Republic: Czech Society of Cardiology, Zuzana
Motovska; Denmark: Danish Society of Cardiology, Erik
Lerkevang Grove; Estonia: Estonian Society of Cardiology, Toomas
Marandi; Finland: Finnish Cardiac Society, Tuomas Kiviniemi; The
Former Yugoslav Republic of Macedonia: Macedonian Society
of Cardiology, Sasko Kedev; France: French Society of Cardiology,
Martine Gilard; Germany: German Cardiac Society, Steffen
Massberg; Greece: Hellenic Society of Cardiology, Dimitrios
Alexopoulos; Hungary: Hungarian Society of Cardiology, Robert
Gabor Kiss; Iceland: Icelandic Society of Cardiology, Ingibjorg
Jona Gudmundsdottir; Ireland: Irish Cardiac Society, Eugène P.
McFadden; Israel: Israel Heart Society, Eli Lev; Italy: Italian
Federation of Cardiology, Leonardo De Luca; Kazakhstan:
Association of Cardiologists of Kazakhstan, Akhmetzhan Sugraliyev;
Kosovo: Kosovo Society of Cardiology, Edmond Haliti;
Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov,
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Netherlands: Netherlands Society of Cardiology, Jurrien M Ten
Berg; Norway: Norwegian Society of Cardiology, Jan Eritsland;
Poland: Polish Cardiac Society, Andrzej Budaj; Portugal:
Portuguese Society of Cardiology, Carlos Tavares Aguiar; Russian
Federation: Russian Society of Cardiology, Dmitry Duplyakov;
San Marino: San Marino Society of Cardiology, Marco Zavatta;
Serbia: Cardiology Society of Serbia, Nebojsa M. Antonijevic;
Slovakia: Slovak Society of Cardiology, Zuzana Motovska;
Slovenia: Slovenian Society of Cardiology, Zlatko Fras; Spain:
Spanish Society of Cardiology, Antonio Tello Montoliu; Sweden:
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